<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cc="http://web.resource.org/cc/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:content="http://purl.org/rss/1.0/modules/content/"  xmlns:podcast="https://podcastindex.org/namespace/1.0"  xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<channel>
		<atom:link href="https://psychopharmacology.libsyn.com/podcast" rel="self" type="application/rss+xml"/>
		<title>Psychopharmacology and Psychiatry Updates</title>
		<pubDate>Thu, 03 Nov 2022 16:00:00 +0000</pubDate>
		<lastBuildDate>Thu, 03 Nov 2022 16:10:43 +0000</lastBuildDate>
		<generator>Libsyn WebEngine 2.0</generator>
		<link>https://psychopharmacologyinstitute.com</link>
		<language>en</language>
		<copyright><![CDATA[]]></copyright>
		<docs>https://psychopharmacologyinstitute.com</docs>
		<managingEditor>support@psychopharmacologyinstitute.com (support@psychopharmacologyinstitute.com)</managingEditor>
		<itunes:summary><![CDATA[Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.]]></itunes:summary>
		<image>
			<url>https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png</url>
			<title>Psychopharmacology and Psychiatry Updates</title>
			<link><![CDATA[https://psychopharmacologyinstitute.com]]></link>
		</image>
		<itunes:author>Psychopharmacology Institute</itunes:author>
		<itunes:keywords>Psychiatry,Psychopharmacology,mentalhealth</itunes:keywords>
		<itunes:category text="Health &amp; Fitness">
			<itunes:category text="Medicine"/>
		</itunes:category>
		<itunes:category text="Science &amp; Medicine"/>
		<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
		<itunes:explicit>false</itunes:explicit>
		<itunes:owner>
			<itunes:name><![CDATA[Psychopharmacology Institute]]></itunes:name>
			<itunes:email>support@psychopharmacologyinstitute.com</itunes:email>
		</itunes:owner>
		<description><![CDATA[Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.]]></description>
		<itunes:subtitle><![CDATA[Practical updates on psychotropic medications and clinical psychiatry for mental health clinicians.]]></itunes:subtitle>
		<itunes:type>episodic</itunes:type>
		


		<podcast:locked owner="support@psychopharmacologyinstitute.com">no</podcast:locked>
		
		<item>
			<title>Patient, Caregiver, and Environmental Factors Underlying BPSD</title>
			<itunes:title>Patient, Caregiver, and Environmental Factors Underlying BPSD</itunes:title>
			<pubDate>Thu, 03 Nov 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[bddca12b-157d-4a71-a3c8-5582ee467e38]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/patient-caregiver-and-environmental-factors-underlying-bpsd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the patient factors underlying BPSD, such as neurodegeneration, acute medical issues, medication changes, pain, and psychiatric diagnoses. It also explains caregiver and environmental factors and the concept of the “broken brain.” </p> <p>Faculty: Lauren Gerlach, D.O. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-behavioral-and-psychological-symptoms-of-dementia-2630?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> <strong>Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/understanding-patient-caregiver-and-enviromental-factors-2630-5192?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> <strong>Understanding Patient, Caregiver, and Enviromental Factors</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the patient factors underlying BPSD, such as neurodegeneration, acute medical issues, medication changes, pain, and psychiatric diagnoses. It also explains caregiver and environmental factors and the concept of the “broken brain.” </p> <p>Faculty: Lauren Gerlach, D.O.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-behavioral-and-psychological-symptoms-of-dementia-2630?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/understanding-patient-caregiver-and-enviromental-factors-2630-5192?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC193"> Understanding Patient, Caregiver, and Enviromental Factors</a></li> </ul>]]></content:encoded>
			<enclosure length="16558081" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC193.mp3?dest-id=744856" />
			<itunes:duration>11:29</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the patient factors underlying BPSD, such as neurodegeneration, acute medical issues, medication changes, pain, and psychiatric diagnoses. It also explains caregiver and environmental factors and the concept of the “broken...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Long-Term Treatment With Methylphenidate in Preschool Children</title>
			<itunes:title>Long-Term Treatment With Methylphenidate in Preschool Children</itunes:title>
			<pubDate>Sat, 29 Oct 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[015bfaf5-7e0a-48b9-982b-21e1688ca837]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/long-term-treatment-with-methylphenidate-in-preschool-children]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Is it safe to use stimulants in preschool children with ADHD? In this episode, we discuss the long-term symptom control and safety of an ER methylphenidate compound in preschool children 4 to <6 years. </p> <p>Faculty: David Rosenberg, M.D.<br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC192"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-01-2740?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC192"> <strong>Earn 0.5 CMEs: Smart Take Vol. 1</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/long-term-treatment-with-extended-release-methylphenidate-treatment-in-children-aged-4-to-6-years-2740-5284?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC192"> <strong>Long-Term Treatment With Extended-Release Methylphenidate Treatment in Younger Children</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Is it safe to use stimulants in preschool children with ADHD? In this episode, we discuss the long-term symptom control and safety of an ER methylphenidate compound in preschool children 4 to ]]></content:encoded>
			<enclosure length="14402666" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC192.mp3?dest-id=744856" />
			<itunes:duration>09:59</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Is it safe to use stimulants in preschool children with ADHD? In this episode, we discuss the long-term symptom control and safety of an ER methylphenidate compound in preschool children 4 to <6 years.  Faculty: David Rosenberg, M.D. Host:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Use of Psychotropics in Patients With Hepatic Issues</title>
			<itunes:title>Use of Psychotropics in Patients With Hepatic Issues</itunes:title>
			<pubDate>Mon, 24 Oct 2022 15:47:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[673aca29-3598-47ba-93e7-1611c594f04a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/use-of-psychotropics-in-patients-with-hepatic-issues]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How to determine whether hepatic impairment can affect drug metabolism? This episode discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. It also clarifies dosing considerations for specific medications, such as clozapine and valproate, in the context of patients with hepatic issues. </p> <p>Guest: Jonathan Meyer, M.D. <br /> Interviewer: Mohan Gautam, M.D. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC191"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-interview-2655?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC191"> <strong>Earn 0.5 CMEs: Use of Psychotropics in Patients With Hepatic Issues - Interview with Jonathan M. Meyer, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How to determine whether hepatic impairment can affect drug metabolism? This episode discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. It also clarifies dosing considerations for specific medications, such as clozapine and valproate, in the context of patients with hepatic issues. </p> <p>Guest: Jonathan Meyer, M.D.  Interviewer: Mohan Gautam, M.D.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC191"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-interview-2655?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC191"> Earn 0.5 CMEs: Use of Psychotropics in Patients With Hepatic Issues - Interview with Jonathan M. Meyer, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="26838393" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC191.mp3?dest-id=744856" />
			<itunes:duration>18:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How to determine whether hepatic impairment can affect drug metabolism? This episode discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. It also clarifies dosing considerations for specific...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Important Considerations for Switching to Clozapine</title>
			<itunes:title>Important Considerations for Switching to Clozapine</itunes:title>
			<pubDate>Wed, 19 Oct 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[dc5eb5bc-5b51-4cc1-bc8a-8a3c88dff11b]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/important-considerations-for-switching-to-clozapine]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How to titrate clozapine in inpatients and outpatients? In this episode, we discuss important considerations for switching to clozapine, including the indications and clinical scenarios for using it. This episode also explains precautions while titrating clozapine and how to reduce the preswitch antipsychotic. </p> <p>Faculty: Brian Miller, M.D. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> <strong>Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/important-considerations-for-switching-to-clozapine-2642-5177?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> <strong>Important Considerations for Switching to Clozapine</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How to titrate clozapine in inpatients and outpatients? In this episode, we discuss important considerations for switching to clozapine, including the indications and clinical scenarios for using it. This episode also explains precautions while titrating clozapine and how to reduce the preswitch antipsychotic. </p> <p>Faculty: Brian Miller, M.D.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/important-considerations-for-switching-to-clozapine-2642-5177?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC190"> Important Considerations for Switching to Clozapine</a></li> </ul>]]></content:encoded>
			<enclosure length="21693734" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC190.mp3?dest-id=744856" />
			<itunes:duration>15:03</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How to titrate clozapine in inpatients and outpatients? In this episode, we discuss important considerations for switching to clozapine, including the indications and clinical scenarios for using it. This episode also explains precautions while...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Pharmacologic and Psychosocial Interventions for Reducing Irritability in Youth With ADHD</title>
			<itunes:title>Pharmacologic and Psychosocial Interventions for Reducing Irritability in Youth With ADHD</itunes:title>
			<pubDate>Fri, 14 Oct 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[a55bf3e4-04fa-4e87-bef4-cbf32e712cbd]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/pharmacologic-and-psychosocial-interventions-for-reducing-irritability-in-youth-with-adhd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>In this episode, we discuss the interventions found to be efficacious in youth with ADHD. Specifically, would treatment with stimulants be effective at reducing irritability in youth with ADHD? </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-39-2657?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> <strong>Earn 0.5 CMEs: Quick Take Vol. 39</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/a-mini-review-of-pharmacologic-and-psychosocial-interventions-for-reducing-irritability-among-youth-with-adhd-2657-5229?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> <strong>A Mini-Review of Pharmacologic and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>In this episode, we discuss the interventions found to be efficacious in youth with ADHD. Specifically, would treatment with stimulants be effective at reducing irritability in youth with ADHD? </p> <p>Faculty: Jim Phelps, M.D.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-39-2657?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> Earn 0.5 CMEs: Quick Take Vol. 39</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/a-mini-review-of-pharmacologic-and-psychosocial-interventions-for-reducing-irritability-among-youth-with-adhd-2657-5229?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC189"> A Mini-Review of Pharmacologic and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD</a></li> </ul>]]></content:encoded>
			<enclosure length="13040328" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC189.mp3?dest-id=744856" />
			<itunes:duration>09:02</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[In this episode, we discuss the interventions found to be efficacious in youth with ADHD. Specifically, would treatment with stimulants be effective at reducing irritability in youth with ADHD?  Faculty: Jim Phelps, M.D.  Host: Richard...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Switching From Oral Antipsychotics to LAIs</title>
			<itunes:title>Switching From Oral Antipsychotics to LAIs</itunes:title>
			<pubDate>Sun, 09 Oct 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[699f33cb-6c2a-44ef-a453-b98b6f1d8814]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/switching-from-oral-antipsychotics-to-lais]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses antipsychotic switching from oral antipsychotics to LAIs, including the factors to consider when titrating antipsychotics and establishing PO tolerability before switching to an LAI. </p> <p>Faculty: Brian Miller, M.D. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> <strong>Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/types-of-antipsychotic-switching-between-po-agents-and-from-po-to-lai-2642-5175?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> <strong>Types of Antipsychotic Switching: Between PO Agents and From PO to LAI</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses antipsychotic switching from oral antipsychotics to LAIs, including the factors to consider when titrating antipsychotics and establishing PO tolerability before switching to an LAI. </p> <p>Faculty: Brian Miller, M.D.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/types-of-antipsychotic-switching-between-po-agents-and-from-po-to-lai-2642-5175?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC188"> Types of Antipsychotic Switching: Between PO Agents and From PO to LAI</a></li> </ul>]]></content:encoded>
			<enclosure length="17840798" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC188.mp3?dest-id=744856" />
			<itunes:duration>12:22</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses antipsychotic switching from oral antipsychotics to LAIs, including the factors to consider when titrating antipsychotics and establishing PO tolerability before switching to an LAI.  Faculty: Brian Miller, M.D.  Host:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Medications for Rapid Tranquilization of Agitated Patients</title>
			<itunes:title>Medications for Rapid Tranquilization of Agitated Patients</itunes:title>
			<pubDate>Tue, 04 Oct 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[1789fc04-1d12-4a9f-bbad-6bbcb1d5718e]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/medications-for-rapid-tranquilization-of-agitated-patients]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>In this episode, we discuss a systematic review and network analysis that compares 11 medications for treating severe agitation in the emergency department. Which medications have been shown to work best? </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-39-2657?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> <strong>Earn 0.5 CMEs: Quick Take Vol. 39</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/rapid-tranquilization-of-the-agitated-patient-in-the-emergency-department-a-systematic-review-and-network-meta-analysis-2657-5228?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> <strong>Rapid Tranquilization of the Agitated Patient in the Emergency Department: A Systematic Review and Network Meta-Analysis</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>In this episode, we discuss a systematic review and network analysis that compares 11 medications for treating severe agitation in the emergency department. Which medications have been shown to work best? </p> <p>Faculty: Jim Phelps, M.D.  Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-39-2657?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> Earn 0.5 CMEs: Quick Take Vol. 39</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/rapid-tranquilization-of-the-agitated-patient-in-the-emergency-department-a-systematic-review-and-network-meta-analysis-2657-5228?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC187"> Rapid Tranquilization of the Agitated Patient in the Emergency Department: A Systematic Review and Network Meta-Analysis</a></li> </ul>]]></content:encoded>
			<enclosure length="12438467" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC187.mp3?dest-id=744856" />
			<itunes:duration>08:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[In this episode, we discuss a systematic review and network analysis that compares 11 medications for treating severe agitation in the emergency department. Which medications have been shown to work best?  Faculty: Jim Phelps, M.D.  Host:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Strategies for Antipsychotic Switching</title>
			<itunes:title>Strategies for Antipsychotic Switching</itunes:title>
			<pubDate>Thu, 29 Sep 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ad8019a7-f166-4bfa-b9e8-e36057fb4cda]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/strategies-for-antipsychotic-switching]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Which is the preferred strategy for switching from one antipsychotic to another?<br /> This episode discusses strategies for antipsychotic switching: Abrupt, cross-taper, taper, and plateau cross-taper switch.                              </p> <p>Faculty: Brian Miller, M.D.<br /> Hosts: Jessica Diaz, M.D., Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> <strong>Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/strategies-for-antipsychotic-switching-2642-5174?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> <strong>Strategies for Antipsychotic Switching</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Which is the preferred strategy for switching from one antipsychotic to another? This episode discusses strategies for antipsychotic switching: Abrupt, cross-taper, taper, and plateau cross-taper switch.                              </p> <p>Faculty: Brian Miller, M.D. Hosts: Jessica Diaz, M.D., Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/strategies-for-antipsychotic-switching-2642-5174?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC186"> Strategies for Antipsychotic Switching</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="14278532" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC186.mp3?dest-id=744856" />
			<itunes:duration>09:54</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Which is the preferred strategy for switching from one antipsychotic to another? This episode discusses strategies for antipsychotic switching: Abrupt, cross-taper, taper, and plateau cross-taper switch.             ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>The Psychopharmacology of Eating Disorders</title>
			<itunes:title>The Psychopharmacology of Eating Disorders</itunes:title>
			<pubDate>Sat, 24 Sep 2022 16:00:04 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[724c3108-554a-40b9-a76f-dd9e592f4802]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/the-psychopharmacology-of-eating-disorders]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Are there FDA-approved medications for eating disorders? In this episode, we discuss management strategies for eating disorders, including the use of FDA-approved medications, the importance of cognitive–behavioral interventions, and the need to reduce stigma in these disorders. </p> <p>Guest: Timothy Brewerton, M.D. <br /> Interviewer: Wegdan Rashad, M.D. <br /> Hosts: Jessica Diaz, M.D.; Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC185"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-feeding-and-eating-disorders-interview-2634?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC185"> <strong>Earn 0.5 CMEs: The Psychopharmacology of Feeding and Eating Disorders - Interview with Timothy Brewerton, M.D.,DLFAPA, FAED, DFAACAP, CEDS-S</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Are there FDA-approved medications for eating disorders? In this episode, we discuss management strategies for eating disorders, including the use of FDA-approved medications, the importance of cognitive–behavioral interventions, and the need to reduce stigma in these disorders. </p> <p>Guest: Timothy Brewerton, M.D.  Interviewer: Wegdan Rashad, M.D.  Hosts: Jessica Diaz, M.D.; Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC185"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-of-feeding-and-eating-disorders-interview-2634?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC185"> Earn 0.5 CMEs: The Psychopharmacology of Feeding and Eating Disorders - Interview with Timothy Brewerton, M.D.,DLFAPA, FAED, DFAACAP, CEDS-S</a></li> </ul>]]></content:encoded>
			<enclosure length="29133616" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC185.mp3?dest-id=744856" />
			<itunes:duration>20:13</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Are there FDA-approved medications for eating disorders? In this episode, we discuss management strategies for eating disorders, including the use of FDA-approved medications, the importance of cognitive–behavioral interventions, and the need to...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Relative Contraindications to Antipsychotic Switching</title>
			<itunes:title>Relative Contraindications to Antipsychotic Switching</itunes:title>
			<pubDate>Mon, 19 Sep 2022 16:00:44 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[8bdf11b0-40ff-412f-88b3-4d89b05565bb]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/relative-contraindications-to-antipsychotic-switching]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What are the contraindications to antipsychotic switching? This episode discusses the relative contraindications of antipsychotic switching, including recent recovery from an acute psychotic episode, current stability on an LAI, and history of violence or severe symptoms. </p> <p>Faculty: Brian Miller, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> <strong>Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/relative-contraindications-to-antipsychotic-switching-2642-5172?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> <strong>Relative Contraindications to Antipsychotic Switching</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>What are the contraindications to antipsychotic switching? This episode discusses the relative contraindications of antipsychotic switching, including recent recovery from an acute psychotic episode, current stability on an LAI, and history of violence or severe symptoms. </p> <p>Faculty: Brian Miller, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/antipsychotic-switching-intersection-of-art-and-science-2642?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/relative-contraindications-to-antipsychotic-switching-2642-5172?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC184"> Relative Contraindications to Antipsychotic Switching</a></li> </ul>]]></content:encoded>
			<enclosure length="11708710" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC184.mp3?dest-id=744856" />
			<itunes:duration>08:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What are the contraindications to antipsychotic switching? This episode discusses the relative contraindications of antipsychotic switching, including recent recovery from an acute psychotic episode, current stability on an LAI, and history of...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Reasons for Stopping Clozapine</title>
			<itunes:title>Reasons for Stopping Clozapine</itunes:title>
			<pubDate>Wed, 14 Sep 2022 16:00:33 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[dc48e3ba-a9c7-4ff4-91bb-649c806c6dbe]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/reasons-for-stopping-clozapine]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Why do patients stop clozapine? <br /> This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy. </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-38-2645?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> <strong>Earn 0.5 CMEs: Quick Take Vol. 38</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/demographic-and-clinical-characteristics-of-patients-who-recommence-clozapine-following-therapy-interruptions-2645-5203?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> <strong>Demographic and Clinical Characteristics of Patients Who Recommence Clozapine Following Therapy Interruptions</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Why do patients stop clozapine?  This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy. </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-38-2645?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> Earn 0.5 CMEs: Quick Take Vol. 38</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/demographic-and-clinical-characteristics-of-patients-who-recommence-clozapine-following-therapy-interruptions-2645-5203?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC183"> Demographic and Clinical Characteristics of Patients Who Recommence Clozapine Following Therapy Interruptions</a></li> </ul>]]></content:encoded>
			<enclosure length="12412762" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC183.mp3?dest-id=744856" />
			<itunes:duration>08:36</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Why do patients stop clozapine?  This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Assessing and Treating an Adolescent With OCD</title>
			<itunes:title>Assessing and Treating an Adolescent With OCD</itunes:title>
			<pubDate>Fri, 09 Sep 2022 16:00:22 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[60acac24-26c3-44de-b7f2-fd7d9dfa7746]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/assessing-and-treating-an-adolescent-with-ocd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Sharpen your clinical skills with a clinical case of an adolescent girl with OCD. This episode also reviews the progression and consequences of the patient’s symptoms, the diagnosis, and the best treatment options for improving her symptoms. </p> <p>Faculty: David Rosenberg, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> <strong>Earn 1 CME: OCD in Children and Adolescents</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/assessing-and-treating-jane-2626-5163?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> <strong>Assessing and Treating Jane</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Sharpen your clinical skills with a clinical case of an adolescent girl with OCD. This episode also reviews the progression and consequences of the patient’s symptoms, the diagnosis, and the best treatment options for improving her symptoms. </p> <p>Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> Earn 1 CME: OCD in Children and Adolescents</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/assessing-and-treating-jane-2626-5163?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC182"> Assessing and Treating Jane</a></li> </ul>]]></content:encoded>
			<enclosure length="11199009" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC182.mp3?dest-id=744856" />
			<itunes:duration>07:46</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Sharpen your clinical skills with a clinical case of an adolescent girl with OCD. This episode also reviews the progression and consequences of the patient’s symptoms, the diagnosis, and the best treatment options for improving her symptoms. ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Mirtazapine for Agitated Behaviors in Dementia</title>
			<itunes:title>Mirtazapine for Agitated Behaviors in Dementia</itunes:title>
			<pubDate>Sun, 04 Sep 2022 16:00:21 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[8c8f602b-aa3b-4e5e-9273-fab385101698]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/mirtazapine-for-agitated-behaviors-in-dementia]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>In this episode, Dr. Phelps discusses a study on the efficacy and safety of mirtazapine for treating agitation in patients with dementia. Would prescribing mirtazapine be worth the risk? </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-38-2645?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> <strong>Earn 0.5 CMEs: Quick Take Vol. 38</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/study-of-mirtazapine-for-agitated-behaviors-in-dementia-symbad-a-randomised-double-blind-placebo-controlled-trial-2645-5200?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> <strong>Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD): A Randomised, Double-Blind, Placebo-Controlled Trial</strong></a></li> </ul> <p> </p> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>In this episode, Dr. Phelps discusses a study on the efficacy and safety of mirtazapine for treating agitation in patients with dementia. Would prescribing mirtazapine be worth the risk? </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-38-2645?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> Earn 0.5 CMEs: Quick Take Vol. 38</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/study-of-mirtazapine-for-agitated-behaviors-in-dementia-symbad-a-randomised-double-blind-placebo-controlled-trial-2645-5200?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC181"> Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD): A Randomised, Double-Blind, Placebo-Controlled Trial</a></li> </ul> <p> </p> <p> </p>]]></content:encoded>
			<enclosure length="14581343" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC181.mp3?dest-id=744856" />
			<itunes:duration>10:06</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[In this episode, Dr. Phelps discusses a study on the efficacy and safety of mirtazapine for treating agitation in patients with dementia. Would prescribing mirtazapine be worth the risk?  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.  ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Clinical Tips for Treating Treatment-Resistant OCD in Youth</title>
			<itunes:title>Clinical Tips for Treating Treatment-Resistant OCD in Youth</itunes:title>
			<pubDate>Tue, 30 Aug 2022 16:00:01 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[2ca3ba22-66c5-4243-8d24-97919d3645a6]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/clinical-tips-for-treating-treatment-resistant-ocd-in-youth]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can we use clomipramine in children?<br /> This episode discusses tips for clinicians treating pediatric OCD, follow-up on pediatric OCD symptoms into adulthood, and treatment response in OCD. It also reviews the use of clomipramine for treatment-resistant OCD and its requirements and precautions.</p> <p>Faculty: David Rosenberg, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> <strong>Earn 1 CME: OCD in Children and Adolescents</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clinical-tips-for-treating-pediatric-ocd-long-term-follow-up-and-treatment-resistant-ocd-2626-5161?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> <strong>Clinical Tips for Treating Pediatric OCD, Long-Term Follow-Up, and Treatment-Resistant OCD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Can we use clomipramine in children? This episode discusses tips for clinicians treating pediatric OCD, follow-up on pediatric OCD symptoms into adulthood, and treatment response in OCD. It also reviews the use of clomipramine for treatment-resistant OCD and its requirements and precautions.</p> <p>Faculty: David Rosenberg, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> Earn 1 CME: OCD in Children and Adolescents</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clinical-tips-for-treating-pediatric-ocd-long-term-follow-up-and-treatment-resistant-ocd-2626-5161?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC180"> Clinical Tips for Treating Pediatric OCD, Long-Term Follow-Up, and Treatment-Resistant OCD</a></li> </ul>]]></content:encoded>
			<enclosure length="11211317" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC180.mp3?dest-id=744856" />
			<itunes:duration>07:46</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can we use clomipramine in children? This episode discusses tips for clinicians treating pediatric OCD, follow-up on pediatric OCD symptoms into adulthood, and treatment response in OCD. It also reviews the use of clomipramine for treatment-resistant...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>GAD Psychopharmacology Algorithm</title>
			<itunes:title>GAD Psychopharmacology Algorithm</itunes:title>
			<pubDate>Thu, 25 Aug 2022 16:00:19 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[47638603-9257-49f7-a49e-dda1c9985dff]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/gad-psychopharmacology-algorithm]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How should we treat patients with bipolar disorder and comorbid GAD? In this episode, Dr. David Osser discusses an evidence-based treatment algorithm for the treatment of generalized anxiety disorder. He also clarifies common clinical concerns, such as treating GAD in patients with comorbid conditions and treatment resistance. </p> <p>Guest: David Osser, M.D. <br /> Interviewer: Mohan Gautam, D.O. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/gad-psychopharmacology-algorithm-interview-2581?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> <strong>Earn 0.5 CMEs: GAD Psychopharmacology Algorithm -Interview with David Osser, M.D.</strong></a></li> <li><a href= "https://psychopharm.mobi/algo_live/?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> <strong>Psychopharmacology Algorithms from Psychopharmacology Algorithms Project at the Harvard South Shore Psychiatry Residency Training Program</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How should we treat patients with bipolar disorder and comorbid GAD? In this episode, Dr. David Osser discusses an evidence-based treatment algorithm for the treatment of generalized anxiety disorder. He also clarifies common clinical concerns, such as treating GAD in patients with comorbid conditions and treatment resistance. </p> <p>Guest: David Osser, M.D.  Interviewer: Mohan Gautam, D.O.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/gad-psychopharmacology-algorithm-interview-2581?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> Earn 0.5 CMEs: GAD Psychopharmacology Algorithm -Interview with David Osser, M.D.</a></li> <li><a href= "https://psychopharm.mobi/algo_live/?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC179"> Psychopharmacology Algorithms from Psychopharmacology Algorithms Project at the Harvard South Shore Psychiatry Residency Training Program</a></li> </ul>]]></content:encoded>
			<enclosure length="27390100" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC179.mp3?dest-id=744856" />
			<itunes:duration>19:00</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How should we treat patients with bipolar disorder and comorbid GAD? In this episode, Dr. David Osser discusses an evidence-based treatment algorithm for the treatment of generalized anxiety disorder. He also clarifies common clinical concerns, such...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Guidelines for Managing Pediatric OCD</title>
			<itunes:title>Guidelines for Managing Pediatric OCD</itunes:title>
			<pubDate>Sat, 20 Aug 2022 16:00:29 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[4a5217c5-df18-43b6-bbbf-5f5fd8039932]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/guidelines-for-managing-pediatric-ocd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What are the FDA-approved medications for pediatric OCD? This episode discusses the guidelines for the management of pediatric OCD, including the treatment for mild, moderate, and severe OCD symptoms, as well as the recommended treatment for remission and maintenance, partial response, and nonresponse. It also examines medication dosing guidelines and FDA-approved medications. </p> <p>Faculty: David Rosenberg, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> <strong>Earn 1 CME: OCD in Children and Adolescents</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/guidelines-for-the-management-of-pediatric-ocd-2626-5159?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> <strong>Guidelines for the Management of Pediatric OCD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>What are the FDA-approved medications for pediatric OCD? This episode discusses the guidelines for the management of pediatric OCD, including the treatment for mild, moderate, and severe OCD symptoms, as well as the recommended treatment for remission and maintenance, partial response, and nonresponse. It also examines medication dosing guidelines and FDA-approved medications. </p> <p>Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> Earn 1 CME: OCD in Children and Adolescents</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/guidelines-for-the-management-of-pediatric-ocd-2626-5159?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC178"> Guidelines for the Management of Pediatric OCD</a></li> </ul>]]></content:encoded>
			<enclosure length="25333113" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC178.mp3?dest-id=744856" />
			<itunes:duration>17:34</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What are the FDA-approved medications for pediatric OCD? This episode discusses the guidelines for the management of pediatric OCD, including the treatment for mild, moderate, and severe OCD symptoms, as well as the recommended treatment for remission...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Ketamine Plus Psychotherapy for AUD</title>
			<itunes:title>Ketamine Plus Psychotherapy for AUD</itunes:title>
			<pubDate>Mon, 15 Aug 2022 16:00:13 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ac6df5ed-061f-4934-8bd7-97915e84aba2]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/ketamine-plus-psychotherapy-for-aud]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can ketamine be an effective adjunctive treatment to sustain abstinence from alcohol? In this episode, Dr. Phelps discusses a double-blind, placebo-controlled trial of adjunctive ketamine with mindfulness psychotherapy for treating alcohol use disorder. </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-37-2640?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> Earn 0.5 CMEs: Quick Take Vol. 37</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/adjunctive-ketamine-with-relapse-prevention-based-psychological-therapy-in-the-treatment-of-alcohol-use-disorder-2640-5188?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> <strong>Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Can ketamine be an effective adjunctive treatment to sustain abstinence from alcohol? In this episode, Dr. Phelps discusses a double-blind, placebo-controlled trial of adjunctive ketamine with mindfulness psychotherapy for treating alcohol use disorder. </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-37-2640?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> Earn 0.5 CMEs: Quick Take Vol. 37</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/adjunctive-ketamine-with-relapse-prevention-based-psychological-therapy-in-the-treatment-of-alcohol-use-disorder-2640-5188?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC177"> Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="15562502" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC177.mp3?dest-id=744856" />
			<itunes:duration>10:47</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can ketamine be an effective adjunctive treatment to sustain abstinence from alcohol? In this episode, Dr. Phelps discusses a double-blind, placebo-controlled trial of adjunctive ketamine with mindfulness psychotherapy for treating alcohol use...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Pediatric OCD Comorbid With GAD, MDD, and ASD</title>
			<itunes:title>Pediatric OCD Comorbid With GAD, MDD, and ASD</itunes:title>
			<pubDate>Wed, 10 Aug 2022 16:00:30 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[d0b70572-3325-4ab0-8dd1-51161073fb14]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/pediatric-ocd-comorbid-with-gad-mdd-and-asd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How to untangle pediatric OCD from ASD and GAD? This episode discusses pediatric OCD and its comorbidities: Depression, GAD, and ASD. It includes a discussion on the differences in concerns between OCD and GAD, the assessment of primary and secondary depressive symptoms, and the differences between ASD and OCD rituals. </p> <p>Faculty: David Rosenberg, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> <strong>Earn 1 CME: OCD in Children and Adolescents</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/pediatric-ocd-comorbidity-with-depression-anxiety-disorders-and-asd-2626-5157?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> <strong>Pediatric OCD Comorbidity With Depression, Anxiety Disorders, and ASD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How to untangle pediatric OCD from ASD and GAD? This episode discusses pediatric OCD and its comorbidities: Depression, GAD, and ASD. It includes a discussion on the differences in concerns between OCD and GAD, the assessment of primary and secondary depressive symptoms, and the differences between ASD and OCD rituals. </p> <p>Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/ocd-in-children-and-adolescents-2626?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> Earn 1 CME: OCD in Children and Adolescents</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/pediatric-ocd-comorbidity-with-depression-anxiety-disorders-and-asd-2626-5157?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC176"> Pediatric OCD Comorbidity With Depression, Anxiety Disorders, and ASD</a></li> </ul>]]></content:encoded>
			<enclosure length="16708944" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC176.mp3?dest-id=744856" />
			<itunes:duration>11:35</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How to untangle pediatric OCD from ASD and GAD? This episode discusses pediatric OCD and its comorbidities: Depression, GAD, and ASD. It includes a discussion on the differences in concerns between OCD and GAD, the assessment of primary and secondary...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>rTMS for Smoking Cessation</title>
			<itunes:title>rTMS for Smoking Cessation</itunes:title>
			<pubDate>Fri, 05 Aug 2022 16:00:23 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[1d49a219-7c7f-4128-824f-92abf7cdb57a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/rtms-for-smoking-cessation]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Have you ever imagined using rTMS for patients who struggle to quit smoking?<br /> This episode discusses a double-blind RCT that assessed the efficacy of rTMS in patients with tobacco use disorder who had at least 1 prior failed attempt to quit.</p> <p>Faculty: Jim Phelps, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-37-2640?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Earn 0.5 CMEs: Quick Take Vol. 37</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/repetitive-transcranial-magnetic-stimulation-for-smoking-cessation-a-pivotal-multicenter-doubleblind-randomized-controlled-trial-2640-5186?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double‐Blind Randomized Controlled Trial</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Have you ever imagined using rTMS for patients who struggle to quit smoking? This episode discusses a double-blind RCT that assessed the efficacy of rTMS in patients with tobacco use disorder who had at least 1 prior failed attempt to quit.</p> <p>Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-37-2640?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Earn 0.5 CMEs: Quick Take Vol. 37</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/repetitive-transcranial-magnetic-stimulation-for-smoking-cessation-a-pivotal-multicenter-doubleblind-randomized-controlled-trial-2640-5186?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC175"> Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double‐Blind Randomized Controlled Trial</a></li> </ul>]]></content:encoded>
			<enclosure length="14625856" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC175.mp3?dest-id=744856" />
			<itunes:duration>10:08</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Have you ever imagined using rTMS for patients who struggle to quit smoking? This episode discusses a double-blind RCT that assessed the efficacy of rTMS in patients with tobacco use disorder who had at least 1 prior failed attempt to quit. Faculty:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Good Psychiatric Management for BPD</title>
			<itunes:title>Good Psychiatric Management for BPD</itunes:title>
			<pubDate>Sun, 31 Jul 2022 16:00:09 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[6ef2f0c5-5f81-407c-ab73-26aadffdec6c]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/good-psychiatric-management-for-bpd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Learn some of the recommendations from the <em>Handbook of Good Psychiatric Management for Borderline Personality Disorder</em>.  This episode addresses the clinical approach and drug management in the good psychiatric management of BPD. </p> <p>Faculty: Paul Links, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> <strong>Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/good-psychiatric-management-for-bpd-2633-5146?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> <strong>Good Psychiatric Management for BPD</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Learn some of the recommendations from the <em>Handbook of Good Psychiatric Management for Borderline Personality Disorder</em>.  This episode addresses the clinical approach and drug management in the good psychiatric management of BPD. </p> <p>Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/good-psychiatric-management-for-bpd-2633-5146?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC174"> Good Psychiatric Management for BPD</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="7735382" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC174.mp3?dest-id=744856" />
			<itunes:duration>08:02</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Learn some of the recommendations from the Handbook of Good Psychiatric Management for Borderline Personality Disorder.  This episode addresses the clinical approach and drug management in the good psychiatric management of BPD.  Faculty:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Tips for Diagnosing and Treating OCRDs</title>
			<itunes:title>Tips for Diagnosing and Treating OCRDs</itunes:title>
			<pubDate>Tue, 26 Jul 2022 16:00:13 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[552653e3-03a6-43ec-88bf-415e664a00d8]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/tips-for-diagnosing-and-treating-ocrds]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How do you distinguish obsessive-compulsive and related disorders from habits? In this episode, we discuss the varying presentations of OCRDs and challenges in their management, including practical recommendations for psychopharmacologic management. </p> <p>Guest: Robert Hudak, M.D. <br /> Interviewer: Wegdan Rashad, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC173"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/obsessive-compulsive-and-related-disorders-interview-2624?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC173"> <strong>Earn 0.5 CMEs: Obsessive-Compulsive and Related Disorders - Interview with Robert Hudak, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How do you distinguish obsessive-compulsive and related disorders from habits? In this episode, we discuss the varying presentations of OCRDs and challenges in their management, including practical recommendations for psychopharmacologic management. </p> <p>Guest: Robert Hudak, M.D.  Interviewer: Wegdan Rashad, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC173"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/obsessive-compulsive-and-related-disorders-interview-2624?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC173"> Earn 0.5 CMEs: Obsessive-Compulsive and Related Disorders - Interview with Robert Hudak, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="29215348" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC173.mp3?dest-id=744856" />
			<itunes:duration>20:16</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How do you distinguish obsessive-compulsive and related disorders from habits? In this episode, we discuss the varying presentations of OCRDs and challenges in their management, including practical recommendations for psychopharmacologic...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Medications Under Investigation for BPD</title>
			<itunes:title>Medications Under Investigation for BPD</itunes:title>
			<pubDate>Thu, 21 Jul 2022 16:00:19 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[0420ef08-87c8-467d-85de-e869e1c2a97a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/medications-under-investigation-for-bpd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and oxytocin. </p> <p>Faculty: Paul Links, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> <strong>Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/omega-3-fatty-acids-methylphenidate-clonidine-doxazosin-memantine-and-oxytocin-for-bpd-2633-5143?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> <strong>Omega-3 Fatty Acids, Methylphenidate, Clonidine, Doxazosin, Memantine, and Oxytocin for BPD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and oxytocin. </p> <p>Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/omega-3-fatty-acids-methylphenidate-clonidine-doxazosin-memantine-and-oxytocin-for-bpd-2633-5143?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC172"> Omega-3 Fatty Acids, Methylphenidate, Clonidine, Doxazosin, Memantine, and Oxytocin for BPD</a></li> </ul>]]></content:encoded>
			<enclosure length="9566461" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC172.mp3?dest-id=744856" />
			<itunes:duration>09:56</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Lithium Efficacy for Preventing Suicide</title>
			<itunes:title>Lithium Efficacy for Preventing Suicide</itunes:title>
			<pubDate>Sat, 16 Jul 2022 16:00:18 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[6302dd07-98b9-4846-a59c-e9b906157550]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/lithium-efficacy-for-preventing-suicide]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Is lithium really effective in patients with a high risk of suicide? In this episode, Dr. Phelps discusses a randomized clinical trial that assessed the efficacy of adding lithium to an existing medication regimen for reducing the rate of suicide-related events in veterans with bipolar disorder and depression. </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-36-2635?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> <strong>Earn 0.5 CMEs: Quick Take Vol. 36</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/lithium-treatment-in-the-prevention-of-repeat-suicide-related-outcomes-in-veterans-with-major-depression-or-bipolar-disorder-2635-5182?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> <strong>Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Is lithium really effective in patients with a high risk of suicide? In this episode, Dr. Phelps discusses a randomized clinical trial that assessed the efficacy of adding lithium to an existing medication regimen for reducing the rate of suicide-related events in veterans with bipolar disorder and depression. </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-36-2635?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> Earn 0.5 CMEs: Quick Take Vol. 36</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/lithium-treatment-in-the-prevention-of-repeat-suicide-related-outcomes-in-veterans-with-major-depression-or-bipolar-disorder-2635-5182?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC171"> Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="15611174" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC171.mp3?dest-id=744856" />
			<itunes:duration>10:49</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Is lithium really effective in patients with a high risk of suicide? In this episode, Dr. Phelps discusses a randomized clinical trial that assessed the efficacy of adding lithium to an existing medication regimen for reducing the rate of...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Mood Stabilizers for BPD</title>
			<itunes:title>Mood Stabilizers for BPD</itunes:title>
			<pubDate>Mon, 11 Jul 2022 21:43:07 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[8b151c00-7b73-45e0-ad52-49a607e480fc]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/mood-stabilizers-for-bpd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Are mood stabilizers effective for borderline personality disorder? This episode discusses the use of lamotrigine and lithium in BPD patients, including possible benefits, concerns, and recommendations regarding these medications. </p> <p>Faculty: Paul Links, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> <strong>Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/mood-stabilizers-for-bpd-lamotrigine-and-lithium-2633-5141?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> <strong>Mood Stabilizers for BPD: Lamotrigine and Lithium</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Are mood stabilizers effective for borderline personality disorder? This episode discusses the use of lamotrigine and lithium in BPD patients, including possible benefits, concerns, and recommendations regarding these medications. </p> <p>Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/mood-stabilizers-for-bpd-lamotrigine-and-lithium-2633-5141?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC170"> Mood Stabilizers for BPD: Lamotrigine and Lithium</a></li> </ul>]]></content:encoded>
			<enclosure length="8121869" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC170.mp3?dest-id=744856" />
			<itunes:duration>08:28</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Are mood stabilizers effective for borderline personality disorder? This episode discusses the use of lamotrigine and lithium in BPD patients, including possible benefits, concerns, and recommendations regarding these medications.  Faculty: Paul...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Anxiety and Sleep Problems in Children and Adolescents</title>
			<itunes:title>Anxiety and Sleep Problems in Children and Adolescents</itunes:title>
			<pubDate>Wed, 06 Jul 2022 16:00:30 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[5bc788e5-3e5d-4708-bd08-28265d731fc2]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/anxiety-and-sleep-problems-in-children-and-adolescents]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Should we target anxiety disorders and sleep-related problems simultaneously? In this episode, Dr. Phelps discusses a narrative review to provide an overview of the evidence of the associations between anxiety disorders and sleep-related problems in children and adolescents. </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-36-2635?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> <strong>Earn 0.5 CMEs: Quick Take Vol. 36</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/treatment-implications-of-sleeprelated-problems-in-pediatric-anxiety-disorders-a-narrative-review-of-the-literature-2635-5181?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> <strong>Treatment Implications of Sleep‑Related Problems in Pediatric Anxiety Disorders: A Narrative Review of the Literature</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Should we target anxiety disorders and sleep-related problems simultaneously? In this episode, Dr. Phelps discusses a narrative review to provide an overview of the evidence of the associations between anxiety disorders and sleep-related problems in children and adolescents. </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-36-2635?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> Earn 0.5 CMEs: Quick Take Vol. 36</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/treatment-implications-of-sleeprelated-problems-in-pediatric-anxiety-disorders-a-narrative-review-of-the-literature-2635-5181?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC169"> Treatment Implications of Sleep‑Related Problems in Pediatric Anxiety Disorders: A Narrative Review of the Literature</a></li> </ul>]]></content:encoded>
			<enclosure length="16068212" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC169.mp3?dest-id=744856" />
			<itunes:duration>11:08</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Should we target anxiety disorders and sleep-related problems simultaneously? In this episode, Dr. Phelps discusses a narrative review to provide an overview of the evidence of the associations between anxiety disorders and sleep-related problems in...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Antipsychotics for Borderline Personality Disorder</title>
			<itunes:title>Antipsychotics for Borderline Personality Disorder</itunes:title>
			<pubDate>Fri, 01 Jul 2022 16:00:24 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[a2257710-da1f-4397-8350-2be18f0fd655]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/antipsychotics-for-borderline-personality-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the use of antipsychotics in patients with borderline personality disorder, including specific information on quetiapine and clozapine and some tips regarding the use of antipsychotics in these cases.              </p> <p>Faculty: Paul Links, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> <strong>Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antipsychotics-for-bpd-2633-5140?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> <strong>Antipsychotics for BPD</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the use of antipsychotics in patients with borderline personality disorder, including specific information on quetiapine and clozapine and some tips regarding the use of antipsychotics in these cases.              </p> <p>Faculty: Paul Links, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacologic-management-of-bpd-recent-developments-2633?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antipsychotics-for-bpd-2633-5140?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC168"> Antipsychotics for BPD</a></li> </ul>]]></content:encoded>
			<enclosure length="6787327" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC168.mp3?dest-id=744856" />
			<itunes:duration>07:05</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the use of antipsychotics in patients with borderline personality disorder, including specific information on quetiapine and clozapine and some tips regarding the use of antipsychotics in these cases.       ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Treating Alcohol Use Disorder</title>
			<itunes:title>Treating Alcohol Use Disorder</itunes:title>
			<pubDate>Sun, 26 Jun 2022 16:00:37 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[505ff949-134c-4f5a-b7dd-27d8a1d1d264]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/treating-alcohol-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Which medications can we offer for alcohol use disorder? This episode will offer practical tips for selecting and initiating medications for managing patients with at-risk drinking and alcohol use disorder.</p> <p>Guest: Joji Suzuki, M.D.<br /> Interviewer: Wegdan Rashad, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC167"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-interview-2623?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC167"> <strong>Earn 0.5 CMEs: What Clinicians Need to KnowAbout Alcohol Use Disorder -Interview with Joji Suzuki, M.D.</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Which medications can we offer for alcohol use disorder? This episode will offer practical tips for selecting and initiating medications for managing patients with at-risk drinking and alcohol use disorder.</p> <p>Guest: Joji Suzuki, M.D. Interviewer: Wegdan Rashad, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC167"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-interview-2623?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC167"> Earn 0.5 CMEs: What Clinicians Need to KnowAbout Alcohol Use Disorder -Interview with Joji Suzuki, M.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="27111969" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC167.mp3?dest-id=744856" />
			<itunes:duration>18:49</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Which medications can we offer for alcohol use disorder? This episode will offer practical tips for selecting and initiating medications for managing patients with at-risk drinking and alcohol use disorder. Guest: Joji Suzuki, M.D. Interviewer: Wegdan...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Topiramate and Stimulant Replacement Therapy for Cocaine Use Disorder</title>
			<itunes:title>Topiramate and Stimulant Replacement Therapy for Cocaine Use Disorder</itunes:title>
			<pubDate>Tue, 21 Jun 2022 16:00:24 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[e32d4268-0695-41db-ad95-3f1261ca9b2a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/topiramate-and-stimulant-replacement-therapy-for-cocaine-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD. </p> <p>Faculty: Andrew Saxon, M.D. <br /> Hosts: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> Earn 1 CME: <span class="notion-enable-hover" data-token-index="1" data-reactroot="">Experimental Pharmacotherapies for Stimulant Use Disorder</span></a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/topiramate-and-methylphenidate-for-cocaine-use-disorder-and-its-comorbidities-2622-5131?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> <strong>Topiramate and Methylphenidate for Cocaine Use Disorder and Its Comorbidities</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD. </p> <p>Faculty: Andrew Saxon, M.D.  Hosts: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/topiramate-and-methylphenidate-for-cocaine-use-disorder-and-its-comorbidities-2622-5131?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC166"> Topiramate and Methylphenidate for Cocaine Use Disorder and Its Comorbidities</a></li> </ul>]]></content:encoded>
			<enclosure length="17804436" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC166.mp3?dest-id=744856" />
			<itunes:duration>12:21</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD. ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Association Between Mood Disorders and COVID-19</title>
			<itunes:title>Association Between Mood Disorders and COVID-19</itunes:title>
			<pubDate>Thu, 16 Jun 2022 16:00:48 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[9723daf9-5a6f-4caf-9db0-38b8b6eb9e7e]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/association-between-mood-disorders-and-covid-19]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>In this episode, we discuss the problem of pre-existing mood disorders increasing the risk of hospitalization and death among people infected with COVID-19. Why does this occur?</p> <p>Faculty: Jim Phelps, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-34-2631?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> <strong>Earn 0.5 CMEs: Quick Take Vol. 34</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/association-between-mood-disorders-and-risk-of-covid-19-infection-hospitalization-and-death-2631-5153?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> <strong>Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>In this episode, we discuss the problem of pre-existing mood disorders increasing the risk of hospitalization and death among people infected with COVID-19. Why does this occur?</p> <p>Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-34-2631?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> Earn 0.5 CMEs: Quick Take Vol. 34</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/association-between-mood-disorders-and-risk-of-covid-19-infection-hospitalization-and-death-2631-5153?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC165"> Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="8745464" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC165.mp3?dest-id=744856" />
			<itunes:duration>09:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[In this episode, we discuss the problem of pre-existing mood disorders increasing the risk of hospitalization and death among people infected with COVID-19. Why does this occur? Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D.       ]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Antidepressants and Naltrexone for Stimulant Use Disorder</title>
			<itunes:title>Antidepressants and Naltrexone for Stimulant Use Disorder</itunes:title>
			<pubDate>Sat, 11 Jun 2022 16:00:56 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[260701ba-3a2b-4e82-a3eb-fde055502a80]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/antidepressants-and-naltrexone-for-stimulant-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the evidence of mirtazapine, bupropion, and naltrexone for stimulant use disorder. Are these promising treatments? Are they really effective? </p> <p>Faculty: Andrew Saxon, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> <strong>Earn 1 CME: <span class="notion-enable-hover" data-token-index="1" data-reactroot="">Experimental Pharmacotherapies for Stimulant Use Disorder</span></strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antidepressants-and-naltrexone-for-methamphetamine-use-disorder-2622-5129?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> <strong><span class="notion-enable-hover" data-token-index="1" data-reactroot="">Antidepressants and Naltrexone for Methamphetamine Use Disorder</span></strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the evidence of mirtazapine, bupropion, and naltrexone for stimulant use disorder. Are these promising treatments? Are they really effective? </p> <p>Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antidepressants-and-naltrexone-for-methamphetamine-use-disorder-2622-5129?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC164"> Antidepressants and Naltrexone for Methamphetamine Use Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="16042111" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC164.mp3?dest-id=744856" />
			<itunes:duration>11:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the evidence of mirtazapine, bupropion, and naltrexone for stimulant use disorder. Are these promising treatments? Are they really effective?  Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>CANMAT Task Force Recommendations for the Use of Ketamine</title>
			<itunes:title>CANMAT Task Force Recommendations for the Use of Ketamine</itunes:title>
			<pubDate>Mon, 06 Jun 2022 16:00:20 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[4256afdf-7426-4db0-9cd2-dc8956209df2]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/canmat-task-force-recommendations-for-the-use-of-ketamine]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can we use ketamine as a maintenance treatment for MDD?<br /> In this episode, Dr. Phelps discusses CANMAT’s recommendations for the use of ketamine for MDD.</p> <p>Faculty: Jim Phelps, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-35-2632?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> <strong>Earn 0.5 CMEs: Quick Take Vol. 35</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-canadian-network-for-mood-and-anxiety-treatments-canmat-task-force-recommendations-for-the-use-of-racemic-ketamine-in-adults-with-major-depressive-disorder-2632-5169?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> <strong>The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults With Major Depressive Disorder</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Can we use ketamine as a maintenance treatment for MDD? In this episode, Dr. Phelps discusses CANMAT’s recommendations for the use of ketamine for MDD.</p> <p>Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-35-2632?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> Earn 0.5 CMEs: Quick Take Vol. 35</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-canadian-network-for-mood-and-anxiety-treatments-canmat-task-force-recommendations-for-the-use-of-racemic-ketamine-in-adults-with-major-depressive-disorder-2632-5169?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC163"> The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults With Major Depressive Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="15324893" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC163.mp3?dest-id=744856" />
			<itunes:duration>10:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can we use ketamine as a maintenance treatment for MDD? In this episode, Dr. Phelps discusses CANMAT’s recommendations for the use of ketamine for MDD. Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder</title>
			<itunes:title>Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder</itunes:title>
			<pubDate>Wed, 01 Jun 2022 16:00:23 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[54457ffc-92e8-4bc4-beea-2599ac10fceb]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/stimulant-replacement-therapies-for-methamphetamine-and-amphetamine-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying ADHD. </p> <p>Faculty: Andrew Saxon, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> <strong>Earn 1 CME: <span class="notion-enable-hover" data-token-index="1" data-reactroot="">Experimental Pharmacotherapies for Stimulant Use Disorder</span></strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/stimulant-replacement-therapies-for-methamphetamine-and-amphetamine-use-disorder-2622-5128?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> <strong><span class="notion-enable-hover" data-token-index="1" data-reactroot="">Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder</span></strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying ADHD. </p> <p>Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/stimulant-replacement-therapies-for-methamphetamine-and-amphetamine-use-disorder-2622-5128?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC162"> Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="14734316" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC162.mp3?dest-id=744856" />
			<itunes:duration>10:13</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Premenstrual Mood Syndromes</title>
			<itunes:title>Premenstrual Mood Syndromes</itunes:title>
			<pubDate>Fri, 27 May 2022 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b285011d-1020-41c9-84a1-d12e1441e4e5]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/premenstrual-mood-syndromes]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What is the first-line treatment for premenstrual mood syndromes? In this episode, Dr. Lauren Osborne discusses premenstrual mood syndromes and offers valuable insights regarding their management. She also discusses novel medications, such as brexanolone and drospirenone. </p> <p>Guest: Lauren Osborne, M.D. <br /> Interviewer: Wegdan Rashad, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC161"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/premenstrual-mood-syndromes-interview-2620?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC161"> <strong>Earn 0.5 CMEs: Premenstrual Mood Syndromes -Interview with Lauren Osborne, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>What is the first-line treatment for premenstrual mood syndromes? In this episode, Dr. Lauren Osborne discusses premenstrual mood syndromes and offers valuable insights regarding their management. She also discusses novel medications, such as brexanolone and drospirenone. </p> <p>Guest: Lauren Osborne, M.D.  Interviewer: Wegdan Rashad, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC161"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/premenstrual-mood-syndromes-interview-2620?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC161"> Earn 0.5 CMEs: Premenstrual Mood Syndromes -Interview with Lauren Osborne, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="27493147" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC161.mp3?dest-id=744856" />
			<itunes:duration>19:04</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What is the first-line treatment for premenstrual mood syndromes? In this episode, Dr. Lauren Osborne discusses premenstrual mood syndromes and offers valuable insights regarding their management. She also discusses novel medications, such as...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Stimulant Use Disorder: Diagnosis and Assessment</title>
			<itunes:title>Stimulant Use Disorder: Diagnosis and Assessment</itunes:title>
			<pubDate>Sun, 22 May 2022 16:00:01 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[86a0761e-26e1-497c-9672-d3ef71caa580]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/stimulant-use-disorder-diagnosis-and-assessment]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and medical side effects. </p> <p>Faculty: Andrew Saxon, M.D.<br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> <strong>Earn 1 CME: <span class="notion-enable-hover" data-token-index="1" data-reactroot="">Experimental Pharmacotherapies for Stimulant Use Disorder</span></strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/stimulants-use-course-assessment-and-diagnosis-2622-5126?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> <strong><span class="notion-enable-hover" data-token-index="1" data-reactroot="">Stimulants Use: Course, Assessment, and Diagnosis</span></strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and medical side effects. </p> <p>Faculty: Andrew Saxon, M.D. Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/pharmacotherapies-for-stimulant-use-disorder-2622?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/stimulants-use-course-assessment-and-diagnosis-2622-5126?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC160"> Stimulants Use: Course, Assessment, and Diagnosis</a></li> </ul>]]></content:encoded>
			<enclosure length="15089164" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC160.mp3?dest-id=744856" />
			<itunes:duration>10:28</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Zuranolone for Postpartum Depression</title>
			<itunes:title>Zuranolone for Postpartum Depression</itunes:title>
			<pubDate>Tue, 17 May 2022 16:00:29 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[17c6c5e0-dfe3-44ed-81d4-a1f93d50fd64]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/zuranolone-for-postpartum-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression. </p> <p>Faculty: Jim Phelps, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-35-2632?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Earn 0.5 CMEs: Quick Take Vol. 35</a><br /></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/effect-of-zuranolone-vs-placebo-in-postpartum-depression-2632-5166?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Effect of Zuranolone vs Placebo in Postpartum Depression</a></strong></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression. </p> <p>Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-35-2632?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Earn 0.5 CMEs: Quick Take Vol. 35</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/effect-of-zuranolone-vs-placebo-in-postpartum-depression-2632-5166?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC159"> Effect of Zuranolone vs Placebo in Postpartum Depression</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="13527459" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC159.mp3?dest-id=744856" />
			<itunes:duration>09:23</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Long-Term Treatment of First Episode of Psychosis</title>
			<itunes:title>Long-Term Treatment of First Episode of Psychosis</itunes:title>
			<pubDate>Thu, 12 May 2022 16:00:08 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c12f72c8-3e7e-4a65-9f43-8ff311b9b9c7]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/long-term-treatment-of-first-episode-of-psychosis]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and the importance of collaborative treatment. </p> <p>Faculty: Stephen Marder, M.D. <br /> Host: Jessica Diaz, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> <strong>Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/long-term-treatment-of-fep-2611-5117?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> <strong>Long-Term Treatment of FEP</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and the importance of collaborative treatment. </p> <p>Faculty: Stephen Marder, M.D.  Host: Jessica Diaz, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/long-term-treatment-of-fep-2611-5117?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC158"> Long-Term Treatment of FEP</a></li> </ul>]]></content:encoded>
			<enclosure length="12831557" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC158.mp3?dest-id=744856" />
			<itunes:duration>08:54</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia</title>
			<itunes:title>The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia</itunes:title>
			<pubDate>Sat, 07 May 2022 16:00:52 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[3036b699-ea7b-4213-9674-73bcabbd4e9b]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/the-effects-of-antipsychotic-treatment-on-the-brain-of-patients-with-first-episode-schizophrenia]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics? </p> <p>Faculty: Jim Phelps, M.D. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-34-2631?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> <strong>Earn 0.5 CMEs: Quick Take Vol. 34</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-effects-of-antipsychotic-treatment-on-the-brain-of-patients-with-first-episode-schizophrenia-a-selective-review-of-longitudinal-mri-studies-2631-5150?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> <strong>The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies</strong></a></li> </ul> <p> </p> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics? </p> <p>Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-34-2631?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> Earn 0.5 CMEs: Quick Take Vol. 34</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-effects-of-antipsychotic-treatment-on-the-brain-of-patients-with-first-episode-schizophrenia-a-selective-review-of-longitudinal-mri-studies-2631-5150?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC157"> The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies</a></li> </ul> <p> </p> <p> </p>]]></content:encoded>
			<enclosure length="13224018" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC157.mp3?dest-id=744856" />
			<itunes:duration>09:11</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics?  Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.;...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Health Issues in First Episode of Psychosis</title>
			<itunes:title>Health Issues in First Episode of Psychosis</itunes:title>
			<pubDate>Mon, 02 May 2022 16:00:22 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[e6af399e-2cc8-4a95-88bc-d4da04a3c3a2]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/health-issues-in-first-episode-of-psychosis]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness?</p> <p>This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes. </p> <p>Faculty: Stephen Marder, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> <strong>Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/health-concerns-for-first-episode-patients-2611-5115?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> <strong>Health Concerns for First-Episode Patients</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness?</p> <p>This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes. </p> <p>Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/health-concerns-for-first-episode-patients-2611-5115?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156"> Health Concerns for First-Episode Patients</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="13980106" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC156.mp3?dest-id=744856" />
			<itunes:duration>09:43</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness? This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Psychopharmacology for Treatment-Resistant Early Psychosis</title>
			<itunes:title>Psychopharmacology for Treatment-Resistant Early Psychosis</itunes:title>
			<pubDate>Wed, 27 Apr 2022 16:00:39 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[10156b80-e4b7-4751-82b9-8c805cd20c8d]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/psychopharmacology-for-treatment-resistant-early-psychosis]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses treatment-resistant early psychosis, including treatment with LAIs and the use of clozapine for treatment-resistant cases. </p> <p>Faculty: Stephen Marder, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> <strong>Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/psychopharmacology-for-people-with-treatment-resistant-early-psychosis-2611-5114?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> <strong>Psychopharmacology for People With Treatment-Resistant Early Psychosis</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses treatment-resistant early psychosis, including treatment with LAIs and the use of clozapine for treatment-resistant cases. </p> <p>Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/psychopharmacology-for-people-with-treatment-resistant-early-psychosis-2611-5114?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC154"> Psychopharmacology for People With Treatment-Resistant Early Psychosis</a></li> </ul>]]></content:encoded>
			<enclosure length="12371384" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC154.mp3?dest-id=744856" />
			<itunes:duration>08:34</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses treatment-resistant early psychosis, including treatment with LAIs and the use of clozapine for treatment-resistant cases.  Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Assessing and Treating Adult ADHD</title>
			<itunes:title>Assessing and Treating Adult ADHD</itunes:title>
			<pubDate>Fri, 22 Apr 2022 16:00:05 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ae0c628f-ae50-4708-b623-c8535c034253]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/assessing-and-treating-adult-adhd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Does adult-onset ADHD really exist? This episode discusses the neurobiological underpinnings of adult ADHD. It also describes how to assess adults with ADHD, important considerations, and some management strategies. </p> <p>Guest: Oscar Bukstein, M.D. <br /> Interviewer: Mohan Gautam, D.O. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC155"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-adult-adhd-interview-2616?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC155"> <strong>Earn 0.5 CMEs: The Clinical Guide to Adult ADHD -Interview with Oscar Bukstein, M.D., M.P.H.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Does adult-onset ADHD really exist? This episode discusses the neurobiological underpinnings of adult ADHD. It also describes how to assess adults with ADHD, important considerations, and some management strategies. </p> <p>Guest: Oscar Bukstein, M.D.  Interviewer: Mohan Gautam, D.O.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC155"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-adult-adhd-interview-2616?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC155"> Earn 0.5 CMEs: The Clinical Guide to Adult ADHD -Interview with Oscar Bukstein, M.D., M.P.H.</a></li> </ul>]]></content:encoded>
			<enclosure length="28010999" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC155.mp3?dest-id=744856" />
			<itunes:duration>19:26</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Does adult-onset ADHD really exist? This episode discusses the neurobiological underpinnings of adult ADHD. It also describes how to assess adults with ADHD, important considerations, and some management strategies.  Guest: Oscar Bukstein,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Medications for Binge Eating Disorder</title>
			<itunes:title>Medications for Binge Eating Disorder</itunes:title>
			<pubDate>Sun, 17 Apr 2022 16:00:59 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[cb066e31-f561-4c38-b66e-2665e7f7695a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/medications-for-binge-eating-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Is binge eating an addictive disorder or an impulse-control disorder? In this episode, Dr. Phelps summarizes the evidence of efficacy of several medications for binge eating disorder. He also discusses the psychopathology and neuropharmacology of binge eating disorder. </p> <p>Faculty: Jim Phelps, M.D. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-33-2621?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> <strong>Earn 0.5 CMEs: Quick Take Vol. 33</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/prospects-for-new-drugs-to-treat-binge-eating-disorder-insights-from-psychopathology-and-neuropharmacology-2621-5138?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> <strong>Prospects for New Drugs To Treat Binge Eating Disorder: Insights From Psychopathology and Neuropharmacology</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Is binge eating an addictive disorder or an impulse-control disorder? In this episode, Dr. Phelps summarizes the evidence of efficacy of several medications for binge eating disorder. He also discusses the psychopathology and neuropharmacology of binge eating disorder. </p> <p>Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-33-2621?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> Earn 0.5 CMEs: Quick Take Vol. 33</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/prospects-for-new-drugs-to-treat-binge-eating-disorder-insights-from-psychopathology-and-neuropharmacology-2621-5138?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC153"> Prospects for New Drugs To Treat Binge Eating Disorder: Insights From Psychopathology and Neuropharmacology</a></li> </ul>]]></content:encoded>
			<enclosure length="17341755" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC153.mp3?dest-id=744856" />
			<itunes:duration>12:02</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Is binge eating an addictive disorder or an impulse-control disorder? In this episode, Dr. Phelps summarizes the evidence of efficacy of several medications for binge eating disorder. He also discusses the psychopathology and neuropharmacology of...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Antipsychotics for First  Episodes of Psychosis</title>
			<itunes:title>Antipsychotics for First  Episodes of Psychosis</itunes:title>
			<pubDate>Tue, 12 Apr 2022 16:00:17 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ce678840-9d6a-41f3-b8ec-ba7f58cd65c6]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/antipsychotics-for-first-episodes-of-psychosis]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses considerations when treating first-episode psychosis with antipsychotics, treatment principles and response, and early predictors of poor long-term course. </p> <p>Faculty: Stephen Marder, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> <strong>Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/management-of-first-episodes-antipsychotics-2611-5112?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> <strong>Management of First Episodes: Antipsychotics</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses considerations when treating first-episode psychosis with antipsychotics, treatment principles and response, and early predictors of poor long-term course. </p> <p>Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/management-of-first-episodes-antipsychotics-2611-5112?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC152"> Management of First Episodes: Antipsychotics</a></li> </ul>]]></content:encoded>
			<enclosure length="13049105" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC152.mp3?dest-id=744856" />
			<itunes:duration>09:03</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses considerations when treating first-episode psychosis with antipsychotics, treatment principles and response, and early predictors of poor long-term course.  Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D.,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Effects on Suicidal Risk With Different Medications</title>
			<itunes:title>Effects on Suicidal Risk With Different Medications</itunes:title>
			<pubDate>Thu, 07 Apr 2022 16:00:48 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[0f97964d-6a18-40b1-b7ab-c04769389bf7]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/effects-on-suicidal-risk-with-different-medications]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses whether clozapine and other medications can reduce the risk of suicide. Is it a "class effect" of antipsychotics, or is it specific to clozapine? </p> <p>Faculty: Jim Phelps, M.D. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-33-2621?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> <strong>Earn 0.5 CMEs: Quick Take Vol. 33</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/effects-on-suicidal-risk-comparison-of-clozapine-to-other-newer-medicines-indicated-to-treat-schizophrenia-or-bipolar-disorder-2621-5134?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> <strong>Effects on Suicidal Risk: Comparison of Clozapine to Other Newer Medicines Indicated to Treat Schizophrenia or Bipolar Disorder</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses whether clozapine and other medications can reduce the risk of suicide. Is it a "class effect" of antipsychotics, or is it specific to clozapine? </p> <p>Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-33-2621?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> Earn 0.5 CMEs: Quick Take Vol. 33</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/effects-on-suicidal-risk-comparison-of-clozapine-to-other-newer-medicines-indicated-to-treat-schizophrenia-or-bipolar-disorder-2621-5134?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC151"> Effects on Suicidal Risk: Comparison of Clozapine to Other Newer Medicines Indicated to Treat Schizophrenia or Bipolar Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="13864125" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC151.mp3?dest-id=744856" />
			<itunes:duration>09:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses whether clozapine and other medications can reduce the risk of suicide. Is it a "class effect" of antipsychotics, or is it specific to clozapine?  Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Risks of Using Cannabinoids</title>
			<itunes:title>Risks of Using Cannabinoids</itunes:title>
			<pubDate>Sat, 02 Apr 2022 16:00:20 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[891afa2a-3cc1-425d-948a-e89a3e83d3ce]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/risks-of-using-cannabinoids]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What are the risks associated with cannabinoid use? This episode discusses some risks, such as overdose, increased ER visits, and cardiovascular risks as well as the effects on pulmonary health. </p> <p>Faculty: Diana Martinez, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> <strong>Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/cannabinoids-risks-for-patients-2614-5107?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> <strong>Cannabinoids and Risks for Patients</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>What are the risks associated with cannabinoid use? This episode discusses some risks, such as overdose, increased ER visits, and cardiovascular risks as well as the effects on pulmonary health. </p> <p>Faculty: Diana Martinez, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/cannabinoids-risks-for-patients-2614-5107?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC150"> Cannabinoids and Risks for Patients</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="14906095" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC150.mp3?dest-id=744856" />
			<itunes:duration>10:22</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What are the risks associated with cannabinoid use? This episode discusses some risks, such as overdose, increased ER visits, and cardiovascular risks as well as the effects on pulmonary health.  Faculty: Diana Martinez, M.D.  Hosts: Jessica...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Lithium: How to Manage Dosage</title>
			<itunes:title>Lithium: How to Manage Dosage</itunes:title>
			<pubDate>Mon, 28 Mar 2022 16:00:52 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[8387f41e-178b-4bc2-80cb-a28c48c57a83]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/lithium-how-to-manage-dosage]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How do you titrate lithium doses? In this episode, Dr. David Osser discusses practical insights on lithium dosing and monitoring strategies. </p> <p>Guest: David Osser, M.D. <br /> Interviewer: Mohan Gautam, D.O. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC149"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/lithium-how-to-manage-dosage-and-side-effects-and-persuade-patients-to-take-it-interview-2610?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC149"> <strong>Earn 0.5 CMEs: Lithium: How to Manage Dosage andSide Effects and Persuade Patients toTake It - Interview with David Osser, M.D.</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>How do you titrate lithium doses? In this episode, Dr. David Osser discusses practical insights on lithium dosing and monitoring strategies. </p> <p>Guest: David Osser, M.D.  Interviewer: Mohan Gautam, D.O.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC149"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/lithium-how-to-manage-dosage-and-side-effects-and-persuade-patients-to-take-it-interview-2610?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC149"> Earn 0.5 CMEs: Lithium: How to Manage Dosage andSide Effects and Persuade Patients toTake It - Interview with David Osser, M.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="28276194" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC149.mp3?dest-id=744856" />
			<itunes:duration>19:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How do you titrate lithium doses? In this episode, Dr. David Osser discusses practical insights on lithium dosing and monitoring strategies.  Guest: David Osser, M.D.  Interviewer: Mohan Gautam, D.O.  Hosts: Jessica Diaz, M.D.; Flavio...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>CBD as a Medication</title>
			<itunes:title>CBD as a Medication</itunes:title>
			<pubDate>Wed, 23 Mar 2022 04:00:17 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[85cb222d-2dec-440c-aece-7fbe57295a6b]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/cbd-as-a-medication]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can we use CBD for psychiatric disorders?<br /> This episode discusses the evidence for medical uses of CBD for various disorders, such as childhood epilepsy, schizophrenia, social anxiety disorder, opioid use disorder, and cannabis use disorder.                                              </p> <p>Faculty: Diana Martinez, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> <strong>Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/understanding-the-evidence-for-cbd-2614-5106?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> Understanding the Evidence for CBD</a></strong></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Can we use CBD for psychiatric disorders? This episode discusses the evidence for medical uses of CBD for various disorders, such as childhood epilepsy, schizophrenia, social anxiety disorder, opioid use disorder, and cannabis use disorder.                                              </p> <p>Faculty: Diana Martinez, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/understanding-the-evidence-for-cbd-2614-5106?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC148"> Understanding the Evidence for CBD</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="11489908" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC148.mp3?dest-id=744856" />
			<itunes:duration>07:58</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can we use CBD for psychiatric disorders? This episode discusses the evidence for medical uses of CBD for various disorders, such as childhood epilepsy, schizophrenia, social anxiety disorder, opioid use disorder, and cannabis use disorder.  ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>SSRIs and Suicidality</title>
			<itunes:title>SSRIs and Suicidality</itunes:title>
			<pubDate>Fri, 18 Mar 2022 04:00:05 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[3a4458c3-2438-4e06-8a0f-7eea115f09dc]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/ssris-and-suicidality]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Do SSRIs really increase suicide risk? This episode discusses the controversial literature regarding the effect of antidepressant initiation on suicidal ideation. </p> <p>Faculty: Jim Phelps, M.D. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-32-2617?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> Earn 0.5 CMEs: Quick Take Vol. 32</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/suicidality-and-self-injury-with-selective-serotonin-reuptake-inhibitors-in-youth-occurrence-predictors-and-timing-2617-5122?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> <strong>Suicidality and Self-Injury With Selective Serotonin Reuptake Inhibitors in Youth: Occurrence, Predictors, and Timing</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Do SSRIs really increase suicide risk? This episode discusses the controversial literature regarding the effect of antidepressant initiation on suicidal ideation. </p> <p>Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-32-2617?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> Earn 0.5 CMEs: Quick Take Vol. 32</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/suicidality-and-self-injury-with-selective-serotonin-reuptake-inhibitors-in-youth-occurrence-predictors-and-timing-2617-5122?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC147"> Suicidality and Self-Injury With Selective Serotonin Reuptake Inhibitors in Youth: Occurrence, Predictors, and Timing</a></li> </ul>]]></content:encoded>
			<enclosure length="13979482" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC147.mp3?dest-id=744856" />
			<itunes:duration>09:41</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Do SSRIs really increase suicide risk? This episode discusses the controversial literature regarding the effect of antidepressant initiation on suicidal ideation.  Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Cannabis and Cognition</title>
			<itunes:title>Cannabis and Cognition</itunes:title>
			<pubDate>Sun, 13 Mar 2022 17:00:57 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c6cf2a22-b810-4a11-90b2-45577f88c12f]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/cannabis-and-cognition]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Does cannabis use cause cognitive deficits? This episode discusses cannabis use and its long-term effects on cognition in adults and younger people. </p> <p>Faculty: Diana Martinez, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> <strong>Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/cannabis-and-cognition-2614-5103?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> Cannabis and Cognition</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Does cannabis use cause cognitive deficits? This episode discusses cannabis use and its long-term effects on cognition in adults and younger people. </p> <p>Faculty: Diana Martinez, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/cannabis-and-cognition-2614-5103?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC146"> Cannabis and Cognition</a></li> </ul>]]></content:encoded>
			<enclosure length="10906855" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC146.mp3?dest-id=744856" />
			<itunes:duration>07:33</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Does cannabis use cause cognitive deficits? This episode discusses cannabis use and its long-term effects on cognition in adults and younger people.  Faculty: Diana Martinez, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Clozapine-Induced Myocarditis</title>
			<itunes:title>Clozapine-Induced Myocarditis</itunes:title>
			<pubDate>Tue, 08 Mar 2022 17:00:27 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[9d0433ae-f619-41f1-8b45-1206c14bdd4d]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/clozapine-induced-myocarditis]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>When should you suspect clozapine-induced myocarditis? Myocarditis has nonspecific manifestations. In this episode, Dr. Phelps explains the clinical presentation and the steps to take if you suspect myocarditis.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-32-2617?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> Earn 0.5 CMEs: Quick Take Vol. 32</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clozapine-induced-myocarditis-electronic-health-register-analysis-of-incidence-timing-clinical-markers-and-diagnostic-accuracy-2617-5119?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> <strong>Clozapine-Induced Myocarditis: Electronic Health Register Analysis of Incidence, Timing, Clinical Markers, and Diagnostic Accuracy</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>When should you suspect clozapine-induced myocarditis? Myocarditis has nonspecific manifestations. In this episode, Dr. Phelps explains the clinical presentation and the steps to take if you suspect myocarditis.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-32-2617?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> Earn 0.5 CMEs: Quick Take Vol. 32</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clozapine-induced-myocarditis-electronic-health-register-analysis-of-incidence-timing-clinical-markers-and-diagnostic-accuracy-2617-5119?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC145"> Clozapine-Induced Myocarditis: Electronic Health Register Analysis of Incidence, Timing, Clinical Markers, and Diagnostic Accuracy</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="14086689" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC145.mp3?dest-id=744856" />
			<itunes:duration>09:46</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[When should you suspect clozapine-induced myocarditis? Myocarditis has nonspecific manifestations. In this episode, Dr. Phelps explains the clinical presentation and the steps to take if you suspect myocarditis. Faculty: Jim Phelps, M.D. Hosts:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Does Cannabis Use Cause Psychiatric Disorders?</title>
			<itunes:title>Does Cannabis Use Cause Psychiatric Disorders?</itunes:title>
			<pubDate>Thu, 03 Mar 2022 17:00:01 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[7b7e2d6e-5d1e-4609-92c8-03535d61e3ff]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/does-cannabis-use-cause-psychiatric-disorders]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses cannabis use in patients with a psychiatric disorder. It also addresses the risk of psychosis in people who use cannabis and the relationship to schizophrenia. </p> <p>Faculty: Diana Martinez, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> <strong>Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/does-cannabis-use-cause-psychiatric-disorders-2614-5102?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> <strong>Does Cannabis Use Cause Psychiatric Disorders?</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses cannabis use in patients with a psychiatric disorder. It also addresses the risk of psychosis in people who use cannabis and the relationship to schizophrenia. </p> <p>Faculty: Diana Martinez, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/medicinal-cannabis-and-the-psychiatric-patient-clinical-harm-vs-novel-treatment-2614?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> Earn 0.75 CMEs: Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/does-cannabis-use-cause-psychiatric-disorders-2614-5102?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC144"> Does Cannabis Use Cause Psychiatric Disorders?</a></li> </ul>]]></content:encoded>
			<enclosure length="13828390" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC144.mp3?dest-id=744856" />
			<itunes:duration>09:35</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses cannabis use in patients with a psychiatric disorder. It also addresses the risk of psychosis in people who use cannabis and the relationship to schizophrenia.  Faculty: Diana Martinez, M.D.  Hosts: Jessica Diaz, M.D.,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Treatment Strategies for Treatment-Resistant OCD</title>
			<itunes:title>Treatment Strategies for Treatment-Resistant OCD</itunes:title>
			<pubDate>Sat, 26 Feb 2022 17:00:50 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[f9dc5770-bc6f-4045-be31-31c1b3dcd107]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/treatment-strategies-for-treatment-resistant-ocd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>When a patient does not respond to an SSRI trial, what is the best strategy—increase the dose, augment with another agent, or switch to another SSRI? In this interview, Dr. Hudak discusses dosing strategies and the treatment of patients with OCD and comorbid psychiatric conditions. </p> <p>Guest: Robert Hudak, M.D. <br /> Interviewer: Mohan Gautam, D.O. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC143"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/treatment-resistant-obsessive-compulsive-disorder-interview-2608?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC143"> <strong>Earn 0.5 CMEs: Treatment-Resistant Obsessive-Compulsive Disorder - Interview with Robert Hudak, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>When a patient does not respond to an SSRI trial, what is the best strategy—increase the dose, augment with another agent, or switch to another SSRI? In this interview, Dr. Hudak discusses dosing strategies and the treatment of patients with OCD and comorbid psychiatric conditions. </p> <p>Guest: Robert Hudak, M.D.  Interviewer: Mohan Gautam, D.O.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC143"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/treatment-resistant-obsessive-compulsive-disorder-interview-2608?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC143"> Earn 0.5 CMEs: Treatment-Resistant Obsessive-Compulsive Disorder - Interview with Robert Hudak, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="28104413" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC143.mp3?dest-id=744856" />
			<itunes:duration>19:30</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[When a patient does not respond to an SSRI trial, what is the best strategy—increase the dose, augment with another agent, or switch to another SSRI? In this interview, Dr. Hudak discusses dosing strategies and the treatment of patients with OCD and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Lithium Augmentation for Psychotic Depression</title>
			<itunes:title>Lithium Augmentation for Psychotic Depression</itunes:title>
			<pubDate>Mon, 21 Feb 2022 17:00:32 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c9194bc5-a4f1-461f-8354-dbbd136f71f8]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/lithium-augmentation-for-psychotic-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses lithium augmentation for psychotic depression, including evidence from different case series and open-label studies. It also addresses some clinical strategies for lithium augmentation. </p> <p>Faculty: David Osser, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> <strong>Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-5-lithium-augmentation-2625-5091?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> <strong>Node 5: Lithium Augmentation</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses lithium augmentation for psychotic depression, including evidence from different case series and open-label studies. It also addresses some clinical strategies for lithium augmentation. </p> <p>Faculty: David Osser, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-5-lithium-augmentation-2625-5091?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC142"> Node 5: Lithium Augmentation</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="12887982" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC142.mp3?dest-id=744856" />
			<itunes:duration>08:56</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses lithium augmentation for psychotic depression, including evidence from different case series and open-label studies. It also addresses some clinical strategies for lithium augmentation.  Faculty: David Osser, M.D. ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Prevention and Treatment Strategies for Agitation and Dementia</title>
			<itunes:title>Prevention and Treatment Strategies for Agitation and Dementia</itunes:title>
			<pubDate>Wed, 16 Feb 2022 17:00:26 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b82ca2fe-8065-4074-9e0b-6ea8ddf98eca]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/prevention-and-treatment-strategies-for-agitation-and-dementia]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Which medications can be used for acute and chronic agitation in dementia?<br /> For acute agitation, you might consider the use of haloperidol. For chronic agitation, you could consider citalopram: Its efficacy has been found to be equal to that of antipsychotics in randomized trials.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-31-2612?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> <strong>Earn 0.5 CMEs: Quick Take Vol. 31</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/agitation-and-dementia-prevention-and-treatment-strategies-in-acute-and-chronic-conditions-2612-5099?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Which medications can be used for acute and chronic agitation in dementia? For acute agitation, you might consider the use of haloperidol. For chronic agitation, you could consider citalopram: Its efficacy has been found to be equal to that of antipsychotics in randomized trials.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-31-2612?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> Earn 0.5 CMEs: Quick Take Vol. 31</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/agitation-and-dementia-prevention-and-treatment-strategies-in-acute-and-chronic-conditions-2612-5099?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC141"> Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions</a></li> </ul>]]></content:encoded>
			<enclosure length="14861585" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC141.mp3?dest-id=744856" />
			<itunes:duration>10:18</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Which medications can be used for acute and chronic agitation in dementia? For acute agitation, you might consider the use of haloperidol. For chronic agitation, you could consider citalopram: Its efficacy has been found to be equal to that of...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Choosing an Antipsychotic for Psychotic Depression</title>
			<itunes:title>Choosing an Antipsychotic for Psychotic Depression</itunes:title>
			<pubDate>Fri, 11 Feb 2022 17:00:09 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[f553a505-1400-45f1-85af-2775940312a5]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/choosing-an-antipsychotic-for-psychotic-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses how to choose an antipsychotic for psychotic depression combination therapy. It also reviews the efficacy and side effects of first- and second-generation antipsychotics and the evidence of SGAs for psychotic depression. </p> <p>Faculty: David Osser, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> <strong>Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-2-choosing-an-antipsychotic-for-psychotic-depression-2625-5089?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> <strong>Node 2: Choosing an Antipsychotic for Psychotic Depression</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses how to choose an antipsychotic for psychotic depression combination therapy. It also reviews the efficacy and side effects of first- and second-generation antipsychotics and the evidence of SGAs for psychotic depression. </p> <p>Faculty: David Osser, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-2-choosing-an-antipsychotic-for-psychotic-depression-2625-5089?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC140"> Node 2: Choosing an Antipsychotic for Psychotic Depression</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="18057089" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC140.mp3?dest-id=744856" />
			<itunes:duration>12:33</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses how to choose an antipsychotic for psychotic depression combination therapy. It also reviews the efficacy and side effects of first- and second-generation antipsychotics and the evidence of SGAs for psychotic depression. ...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Neurological and Psychiatric Sequelae Due to COVID-19</title>
			<itunes:title>Neurological and Psychiatric Sequelae Due to COVID-19</itunes:title>
			<pubDate>Sun, 06 Feb 2022 17:00:26 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[024098f8-6734-4e4c-b4bd-a3cf535fe0fb]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/neurological-and-psychiatric-sequelae-due-to-covid-19]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>COVID-19 infection is associated with new-onset neurological illness but at relatively low absolute rates. On the other hand, rates for new-onset anxiety and mood disorders can be higher, at 7% and 8%, respectively. </p> <p>Faculty: Jim Phelps, M.D. <br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-31-2612?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> <strong>Earn 0.5 CMEs: Quick Take Vol. 31</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/six-month-neurological-and-psychiatric-outcomes-in-236379-survivors-of-covid-19-a-retrospective-cohort-study-using-electronic-health-records-2612-5097?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> <strong>Six-Month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>COVID-19 infection is associated with new-onset neurological illness but at relatively low absolute rates. On the other hand, rates for new-onset anxiety and mood disorders can be higher, at 7% and 8%, respectively. </p> <p>Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-31-2612?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> Earn 0.5 CMEs: Quick Take Vol. 31</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/six-month-neurological-and-psychiatric-outcomes-in-236379-survivors-of-covid-19-a-retrospective-cohort-study-using-electronic-health-records-2612-5097?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC139"> Six-Month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records</a></li> </ul>]]></content:encoded>
			<enclosure length="12277968" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC139.mp3?dest-id=744856" />
			<itunes:duration>08:32</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[COVID-19 infection is associated with new-onset neurological illness but at relatively low absolute rates. On the other hand, rates for new-onset anxiety and mood disorders can be higher, at 7% and 8%, respectively.  Faculty: Jim Phelps,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>SNRIs + Antipsychotics for Psychotic Depression</title>
			<itunes:title>SNRIs + Antipsychotics for Psychotic Depression</itunes:title>
			<pubDate>Tue, 01 Feb 2022 17:00:13 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[2d83b785-1da4-4baf-a2b7-8b30702660b8]]></guid>
			<link><![CDATA[https://traffic.libsyn.com/psychopharmacology/OPC138.mp3]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Which is the best antidepressant for combination treatment in psychotic depression?<br /> This episode includes the use of venlafaxine plus quetiapine and how to choose an antidepressant for combination treatment.</p> <p>Faculty: David Osser, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> <strong>Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-2c-combination-therapy-snris-antipsychotics-2625-5088?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> <strong>Node 2C: Combination Therapy: SNRIs + Antipsychotics</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Which is the best antidepressant for combination treatment in psychotic depression? This episode includes the use of venlafaxine plus quetiapine and how to choose an antidepressant for combination treatment.</p> <p>Faculty: David Osser, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-2c-combination-therapy-snris-antipsychotics-2625-5088?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC138"> Node 2C: Combination Therapy: SNRIs + Antipsychotics</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="15396991" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC138.mp3?dest-id=744856" />
			<itunes:duration>10:40</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Which is the best antidepressant for combination treatment in psychotic depression? This episode includes the use of venlafaxine plus quetiapine and how to choose an antidepressant for combination treatment. Faculty: David Osser, M.D. Hosts: Jessica...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Approaches for Addressing Tobacco Use Disorder</title>
			<itunes:title>Approaches for Addressing Tobacco Use Disorder</itunes:title>
			<pubDate>Thu, 27 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[f6d177b7-60c5-48e1-b8cb-5a20e84fb73c]]></guid>
			<link><![CDATA[https://traffic.libsyn.com/psychopharmacology/OPC137.mp3]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How can we counsel patients about smoking cessation? In this interview, Dr. Joji Suzuki emphasizes the advantages of motivational interviewing and discusses some pharmacologic treatments, such as nicotine replacement therapies, varenicline, and bupropion.</p> <p>Guest: Joji Suzuki, M.D.<br /> Interviewer: Wegdan Rashad, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC137"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-on-tobacco-use-disorder-interview-2609?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC137"> <strong>Earn 0.5 CMEs: The Clinical Guide On Tobacco Use Disorder - Interview with Joji Suzuki, M.D.</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>How can we counsel patients about smoking cessation? In this interview, Dr. Joji Suzuki emphasizes the advantages of motivational interviewing and discusses some pharmacologic treatments, such as nicotine replacement therapies, varenicline, and bupropion.</p> <p>Guest: Joji Suzuki, M.D. Interviewer: Wegdan Rashad, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC137"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-on-tobacco-use-disorder-interview-2609?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC137"> Earn 0.5 CMEs: The Clinical Guide On Tobacco Use Disorder - Interview with Joji Suzuki, M.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="26951242" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC137.mp3?dest-id=744856" />
			<itunes:duration>18:42</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How can we counsel patients about smoking cessation? In this interview, Dr. Joji Suzuki emphasizes the advantages of motivational interviewing and discusses some pharmacologic treatments, such as nicotine replacement therapies, varenicline, and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>ECT the First-Choice Treatment for Psychotic Depression</title>
			<itunes:title>ECT the First-Choice Treatment for Psychotic Depression</itunes:title>
			<pubDate>Sat, 22 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[d01e09a9-e958-4aad-af6d-ee21cd9478e3]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/ect-the-first-choice-treatment-for-psychotic-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the use of ECT for severely ill patients, including its benefits and limitations, as well as the use of ECT as a maintenance treatment.</p> <p>Faculty: David Osser, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> <strong>Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-1-ect-for-severely-ill-patients-2625-5085?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> <strong>Node 1: ECT for Severely Ill Patients</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the use of ECT for severely ill patients, including its benefits and limitations, as well as the use of ECT as a maintenance treatment.</p> <p>Faculty: David Osser, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-psychopharmacology-algorithm-for-psychotic-depression-2625?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> Earn 1.25 CMEs: The Psychopharmacology Algorithm for Psychotic Depression</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/node-1-ect-for-severely-ill-patients-2625-5085?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC136"> Node 1: ECT for Severely Ill Patients</a></li> </ul>]]></content:encoded>
			<enclosure length="14440282" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC136.mp3?dest-id=744856" />
			<itunes:duration>10:01</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the use of ECT for severely ill patients, including its benefits and limitations, as well as the use of ECT as a maintenance treatment. Faculty: David Osser, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Metabolic Characteristics of Newer Second-Generation Antipsychotics</title>
			<itunes:title>Metabolic Characteristics of Newer Second-Generation Antipsychotics</itunes:title>
			<pubDate>Mon, 17 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b930263d-7004-4885-b554-ba7055725a14]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/metabolic-characteristics-of-newer-second-generation-antipsychotics]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>What was the difference among antipsychotics? Over 1 year, lurasidone caused no net weight gain, whereas olanzapine caused a gain of 10 pounds. Perphenazine was associated with a 2 lb. loss vs olanzapine's 9.5 lb. gain.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-30-2604?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> <strong>Earn 0.5 CMEs: Quick Take Vol. 30</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/comparison-of-the-metabolic-characteristics-of-newer-second-generation-antipsychotics-2604-5083?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> <strong>Comparison of the Metabolic Characteristics of Newer Second-Generation Antipsychotics</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>What was the difference among antipsychotics? Over 1 year, lurasidone caused no net weight gain, whereas olanzapine caused a gain of 10 pounds. Perphenazine was associated with a 2 lb. loss vs olanzapine's 9.5 lb. gain.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-30-2604?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> Earn 0.5 CMEs: Quick Take Vol. 30</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/comparison-of-the-metabolic-characteristics-of-newer-second-generation-antipsychotics-2604-5083?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC135"> Comparison of the Metabolic Characteristics of Newer Second-Generation Antipsychotics</a></li> </ul>]]></content:encoded>
			<enclosure length="14650933" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC135.mp3?dest-id=744856" />
			<itunes:duration>10:09</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[What was the difference among antipsychotics? Over 1 year, lurasidone caused no net weight gain, whereas olanzapine caused a gain of 10 pounds. Perphenazine was associated with a 2 lb. loss vs olanzapine's 9.5 lb. gain. Faculty: Jim Phelps, M.D....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Prescribing Antipsychotics During Breastfeeding</title>
			<itunes:title>Prescribing Antipsychotics During Breastfeeding</itunes:title>
			<pubDate>Wed, 12 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c9fdc051-2791-4d26-8be3-a161d1899f84]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/prescribing-antipsychotics-during-breastfeeding]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses first- and second-generation antipsychotics during breastfeeding, including clozapine, the only psychiatric drug nearly always contraindicated.</p> <p>Faculty: Lauren Osborne, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antipsychotics-during-breastfeeding-2615-5075?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> <strong>Antipsychotics During Breastfeeding</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses first- and second-generation antipsychotics during breastfeeding, including clozapine, the only psychiatric drug nearly always contraindicated.</p> <p>Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antipsychotics-during-breastfeeding-2615-5075?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC134"> Antipsychotics During Breastfeeding</a></li> </ul>]]></content:encoded>
			<enclosure length="13370724" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC134.mp3?dest-id=744856" />
			<itunes:duration>09:16</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses first- and second-generation antipsychotics during breastfeeding, including clozapine, the only psychiatric drug nearly always contraindicated. Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Fluvoxamine for Treating COVID-19</title>
			<itunes:title>Fluvoxamine for Treating COVID-19</itunes:title>
			<pubDate>Fri, 07 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[77d84d8b-4f9b-42e6-b84e-f8782cca337a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/fluvoxamine-for-treating-covid-19]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How effective is fluvoxamine in patients with COVID-19? A 2-week course of full-dose fluvoxamine decreased clinical deterioration in outpatients with symptomatic COVID-19 infection.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-30-2604?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> <strong>Earn 0.5 CMEs: Quick Take Vol. 30</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/fluvoxamine-vs-placebo-and-clinical-deterioration-in-outpatients-with-symptomatic-covid-19-2604-5082?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> <strong>Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How effective is fluvoxamine in patients with COVID-19? A 2-week course of full-dose fluvoxamine decreased clinical deterioration in outpatients with symptomatic COVID-19 infection.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-30-2604?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> Earn 0.5 CMEs: Quick Take Vol. 30</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/fluvoxamine-vs-placebo-and-clinical-deterioration-in-outpatients-with-symptomatic-covid-19-2604-5082?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC133"> Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19</a></li> </ul>]]></content:encoded>
			<enclosure length="13934740" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC133.mp3?dest-id=744856" />
			<itunes:duration>09:40</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How effective is fluvoxamine in patients with COVID-19? A 2-week course of full-dose fluvoxamine decreased clinical deterioration in outpatients with symptomatic COVID-19 infection. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Lorena...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Prescribing Antidepressants During Breastfeeding</title>
			<itunes:title>Prescribing Antidepressants During Breastfeeding</itunes:title>
			<pubDate>Sun, 02 Jan 2022 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[0ef625df-600d-4347-8ab2-b6d18c05143b]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/prescribing-antidepressants-during-breastfeeding]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Can we use antidepressants during breastfeeding? This episode discusses the use of antidepressants during breastfeeding, including SSRIs, TCAs, bupropion, and mirtazapine.</p> <p>Faculty: Lauren Osborne, M.D.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antidepressants-during-breastfeeding-2615-5074?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> <strong>Antidepressants During Breastfeeding</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Can we use antidepressants during breastfeeding? This episode discusses the use of antidepressants during breastfeeding, including SSRIs, TCAs, bupropion, and mirtazapine.</p> <p>Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/antidepressants-during-breastfeeding-2615-5074?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC132"> Antidepressants During Breastfeeding</a></li> </ul>]]></content:encoded>
			<enclosure length="17484467" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC132.mp3?dest-id=744856" />
			<itunes:duration>12:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Can we use antidepressants during breastfeeding? This episode discusses the use of antidepressants during breastfeeding, including SSRIs, TCAs, bupropion, and mirtazapine. Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Treatment Strategies for Acute and Chronic Insomnia</title>
			<itunes:title>Treatment Strategies for Acute and Chronic Insomnia</itunes:title>
			<pubDate>Tue, 28 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[83d0f26c-7dac-4f6d-98e9-52a60c2b089e]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/treatment-strategies-for-acute-and-chronic-insomnia]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Is it safe to use atypical antipsychotics for insomnia? Can we use benzodiazepines? This podcast features the different treatments for acute and chronic insomnia. It also addresses the differential diagnoses and some treatment options for insomnia and comorbid depressive disorders.</p> <p>Guest: Charles Reynolds M.D.<br /> Interviewer: Mohan Gautam D.O.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC131"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-sleep-issues-in-psychiatry-interview-2595?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC131"> <strong>Earn 0.5 CMEs: The Clinical Guide to Sleep Issues in Psychiatry - Interview with Charles F. Reynolds III, M.D.</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Is it safe to use atypical antipsychotics for insomnia? Can we use benzodiazepines? This podcast features the different treatments for acute and chronic insomnia. It also addresses the differential diagnoses and some treatment options for insomnia and comorbid depressive disorders.</p> <p>Guest: Charles Reynolds M.D. Interviewer: Mohan Gautam D.O. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC131"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/the-clinical-guide-to-sleep-issues-in-psychiatry-interview-2595?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC131"> Earn 0.5 CMEs: The Clinical Guide to Sleep Issues in Psychiatry - Interview with Charles F. Reynolds III, M.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="26476420" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC131.mp3?dest-id=744856" />
			<itunes:duration>18:22</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Is it safe to use atypical antipsychotics for insomnia? Can we use benzodiazepines? This podcast features the different treatments for acute and chronic insomnia. It also addresses the differential diagnoses and some treatment options for insomnia and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Drug Use in Breastfeeding and Adverse Effects</title>
			<itunes:title>Drug Use in Breastfeeding and Adverse Effects</itunes:title>
			<pubDate>Thu, 23 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[e038b270-1356-40c4-bdbd-ea54c00a606a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/drug-use-in-breastfeeding-and-adverse-effects]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>When it comes to drug use while breastfeeding, what really matters is not the infant dose but the effect on the infant. This episode discusses drug use in breastfeeding, common adverse reactions, and their relationship to maternal dosing.</p> <p>Faculty: Lauren Osborne, M.D.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/drug-use-in-breastfeeding-and-adverse-effects-2615-5073?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Drug Use in Breastfeeding and Adverse Effects</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>When it comes to drug use while breastfeeding, what really matters is not the infant dose but the effect on the infant. This episode discusses drug use in breastfeeding, common adverse reactions, and their relationship to maternal dosing.</p> <p>Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/drug-use-in-breastfeeding-and-adverse-effects-2615-5073?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC130"> Drug Use in Breastfeeding and Adverse Effects</a></li> </ul>]]></content:encoded>
			<enclosure length="11454570" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC130.mp3?dest-id=744856" />
			<itunes:duration>07:56</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[When it comes to drug use while breastfeeding, what really matters is not the infant dose but the effect on the infant. This episode discusses drug use in breastfeeding, common adverse reactions, and their relationship to maternal dosing. Faculty:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Marine Omega-3 Fatty Acid Supplementation for BPD</title>
			<itunes:title>Marine Omega-3 Fatty Acid Supplementation for BPD</itunes:title>
			<pubDate>Sat, 18 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[eb4e207c-2e68-473a-b8e6-1bdcae50dfb4]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/marine-omega-3-fatty-acid-supplementation-for-bpd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>A novel medication approach for borderline personality disorder is discussed. In this meta-analysis of fish oil for borderline personality disorder, the effect size relative to placebo was 0.54 (substantial) and for affective dysregulation was 0.74 (clinically very relevant).</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-29-2603?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> <strong>Earn 0.5 CMEs: Quick Take Vol. 29</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/marine-omega-3-fatty-acid-supplementation-for-borderline-personality-disorder-a-meta-analysis-2603-5065?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> Marine Omega-3 Fatty Acid Supplementation for Borderline Personality Disorder: A Meta-Analysis</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>A novel medication approach for borderline personality disorder is discussed. In this meta-analysis of fish oil for borderline personality disorder, the effect size relative to placebo was 0.54 (substantial) and for affective dysregulation was 0.74 (clinically very relevant).</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-29-2603?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> Earn 0.5 CMEs: Quick Take Vol. 29</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/marine-omega-3-fatty-acid-supplementation-for-borderline-personality-disorder-a-meta-analysis-2603-5065?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC129"> Marine Omega-3 Fatty Acid Supplementation for Borderline Personality Disorder: A Meta-Analysis</a></li> </ul>]]></content:encoded>
			<enclosure length="16750092" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC129.mp3?dest-id=744856" />
			<itunes:duration>11:37</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[A novel medication approach for borderline personality disorder is discussed. In this meta-analysis of fish oil for borderline personality disorder, the effect size relative to placebo was 0.54 (substantial) and for affective dysregulation was 0.74...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Breastfeeding and Estimating Infant Drug Exposure</title>
			<itunes:title>Breastfeeding and Estimating Infant Drug Exposure</itunes:title>
			<pubDate>Mon, 13 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[68ccdb95-2aac-4f56-8183-f27af531c1af]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/breastfeeding-and-estimating-infant-drug-exposure]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses drug use in breastfeeding and how to estimate infant exposure with the milk-to-plasma ratio and the relative infant dose. Learn when these calculations can be helpful.</p> <p>Faculty: Lauren Osborne, M.D.<br /> Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/estimating-infant-exposure-2615-5072?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Estimating Infant Exposure</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses drug use in breastfeeding and how to estimate infant exposure with the milk-to-plasma ratio and the relative infant dose. Learn when these calculations can be helpful.</p> <p>Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D.; Lorena Rodríguez M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/understanding-the-use-of-psychotropic-drugs-in-lactation-2615?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Earn 1 CME: Understanding the Use of Psychotropic Drugs in Lactation</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/estimating-infant-exposure-2615-5072?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC128"> Estimating Infant Exposure</a></li> </ul>]]></content:encoded>
			<enclosure length="18831131" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC128.mp3?dest-id=744856" />
			<itunes:duration>13:04</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses drug use in breastfeeding and how to estimate infant exposure with the milk-to-plasma ratio and the relative infant dose. Learn when these calculations can be helpful. Faculty: Lauren Osborne, M.D. Hosts: Jessica Diaz, M.D.;...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>A Method for Tapering Antipsychotics</title>
			<itunes:title>A Method for Tapering Antipsychotics</itunes:title>
			<pubDate>Wed, 08 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[d1788cb8-d965-418e-bcff-aba4f9d04488]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/a-method-for-tapering-antipsychotics]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>When tapering antipsychotics, conceptualize the process as "finding a new minimum effective dose." This could take months, likely years. This episode features some dose examples.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-29-2603?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> <strong>Earn 0.5 CMEs: Quick Take Vol. 29</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/a-method-for-tapering-antipsychotic-treatment-that-may-minimize-the-risk-of-relapse-2603-5064?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> <strong>A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>When tapering antipsychotics, conceptualize the process as "finding a new minimum effective dose." This could take months, likely years. This episode features some dose examples.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-29-2603?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> Earn 0.5 CMEs: Quick Take Vol. 29</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/a-method-for-tapering-antipsychotic-treatment-that-may-minimize-the-risk-of-relapse-2603-5064?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC127"> A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="15246525" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC127.mp3?dest-id=744856" />
			<itunes:duration>10:34</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[When tapering antipsychotics, conceptualize the process as "finding a new minimum effective dose." This could take months, likely years. This episode features some dose examples. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Management of Psychiatric Comorbidities With Alcohol Use Disorder</title>
			<itunes:title>Management of Psychiatric Comorbidities With Alcohol Use Disorder</itunes:title>
			<pubDate>Fri, 03 Dec 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[a37e862c-7ef4-472b-b05c-2212d47dee58]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/management-of-psychiatric-comorbidities-with-alcohol-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the prevalence and management of psychiatric comorbidities with alcohol use disorder. Learn some strategies for treating alcohol use disorder and comorbid depressive and anxiety disorders. </p> <p>Faculty: Joji Suzuki, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> <strong>Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/psychiatric-comorbidities-with-alcohol-use-disorder-prevalence-and-management-2494-5062?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> <strong>Psychiatric Comorbidities With Alcohol Use Disorder: Prevalence and Management</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the prevalence and management of psychiatric comorbidities with alcohol use disorder. Learn some strategies for treating alcohol use disorder and comorbid depressive and anxiety disorders. </p> <p>Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/psychiatric-comorbidities-with-alcohol-use-disorder-prevalence-and-management-2494-5062?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC126"> Psychiatric Comorbidities With Alcohol Use Disorder: Prevalence and Management</a></li> </ul>]]></content:encoded>
			<enclosure length="18917252" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC126.mp3?dest-id=744856" />
			<itunes:duration>13:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the prevalence and management of psychiatric comorbidities with alcohol use disorder. Learn some strategies for treating alcohol use disorder and comorbid depressive and anxiety disorders.  Faculty: Joji Suzuki, M.D. Hosts:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Tips for Treating Perimenopausal Depression</title>
			<itunes:title>Tips for Treating Perimenopausal Depression</itunes:title>
			<pubDate>Sun, 28 Nov 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[eb3e356b-0211-4dec-b6b3-13d23ae6f3e9]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/tips-for-treating-perimenopausal-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>If your patient has perimenopausal depression, what are the treatment options? This podcast explains different treatment options, such as antidepressants, hormone therapy, and psychotherapy. It also addresses some strategies for managing vasomotor symptoms.</p> <p>Guest: Vivien Burt, M.D.;<br /> Interviewer: Mohan Gautam, D.O.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC125"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/blue-moods-and-hot-flashes-treating-perimenopausal-depression-interview-2590?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC125"> <strong>Earn 0.5 CMEs: <span class="notion-enable-hover" data-token-index="1" data-reactroot="">Blue Moods and Hot Flashes: Treating Perimenopausal Depression - Interview with Vivien K. Burt, M.D., Ph.D.</span></strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>If your patient has perimenopausal depression, what are the treatment options? This podcast explains different treatment options, such as antidepressants, hormone therapy, and psychotherapy. It also addresses some strategies for managing vasomotor symptoms.</p> <p>Guest: Vivien Burt, M.D.; Interviewer: Mohan Gautam, D.O. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC125"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/blue-moods-and-hot-flashes-treating-perimenopausal-depression-interview-2590?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC125"> Earn 0.5 CMEs: Blue Moods and Hot Flashes: Treating Perimenopausal Depression - Interview with Vivien K. Burt, M.D., Ph.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="26875383" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC125.mp3?dest-id=744856" />
			<itunes:duration>18:39</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[If your patient has perimenopausal depression, what are the treatment options? This podcast explains different treatment options, such as antidepressants, hormone therapy, and psychotherapy. It also addresses some strategies for managing vasomotor...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Naltrexone, Acamprosate, and Disulfiram for Alcohol Use Disorder</title>
			<itunes:title>Naltrexone, Acamprosate, and Disulfiram for Alcohol Use Disorder</itunes:title>
			<pubDate>Tue, 23 Nov 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[804d9d42-6f51-466b-a343-7fcfb8917871]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/naltrexoneacamprosateanddisulfiramforalcoholusedisorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses medications for alcohol use disorder, such as naltrexone, acamprosate, and disulfiram. It explains their clinical effects, the goals and benefits of treatment, side effects, liver function monitoring, precautions, contraindications, and dosing. Finally, it emphasizes the patient factors to consider when choosing a treatment.</p> <p>Faculty: Joji Suzuki, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> <strong>Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/pharmacology-in-alcohol-use-disorder-naltrexone-acamprosate-and-disulfiram-2494-5060?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> <strong>Pharmacology in Alcohol Use Disorder: Naltrexone, Acamprosate, and Disulfiram</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses medications for alcohol use disorder, such as naltrexone, acamprosate, and disulfiram. It explains their clinical effects, the goals and benefits of treatment, side effects, liver function monitoring, precautions, contraindications, and dosing. Finally, it emphasizes the patient factors to consider when choosing a treatment.</p> <p>Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/pharmacology-in-alcohol-use-disorder-naltrexone-acamprosate-and-disulfiram-2494-5060?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC124"> Pharmacology in Alcohol Use Disorder: Naltrexone, Acamprosate, and Disulfiram</a></li> </ul>]]></content:encoded>
			<enclosure length="22787742" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC124.mp3?dest-id=744856" />
			<itunes:duration>15:48</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses medications for alcohol use disorder, such as naltrexone, acamprosate, and disulfiram. It explains their clinical effects, the goals and benefits of treatment, side effects, liver function monitoring, precautions,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Subclinical Hypothyroidism in Depressed Adolescents</title>
			<itunes:title>Subclinical Hypothyroidism in Depressed Adolescents</itunes:title>
			<pubDate>Thu, 18 Nov 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[1a167f9d-7845-451e-975a-35a005a62cc5]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/subclinical-hypothyroidism-in-depressed-adolescents]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>From the various references cited in this episode, the metamessage is clear: Thyroid hormone belongs in the treatment toolkit of psychiatric specialists, and monitoring of TSH is our responsibility. </p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-28-2596?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> <strong>Earn 0.5 CMEs: Quick Take Vol. 28</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/increased-prevalence-of-subclinical-hypothyroidism-and-thyroid-autoimmunity-in-depressed-adolescents-results-from-a-clinical-cross-sectional-study-in-comparison-to-the-general-pediatric-population-2596-5054?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> <strong>Increased Prevalence of Subclinical Hypothyroidism and Thyroid Autoimmunity in Depressed Adolescents: Results From a Clinical Cross-Sectional Study in Comparison to the General Pediatric Population</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>From the various references cited in this episode, the metamessage is clear: Thyroid hormone belongs in the treatment toolkit of psychiatric specialists, and monitoring of TSH is our responsibility. </p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-28-2596?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> Earn 0.5 CMEs: Quick Take Vol. 28</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/increased-prevalence-of-subclinical-hypothyroidism-and-thyroid-autoimmunity-in-depressed-adolescents-results-from-a-clinical-cross-sectional-study-in-comparison-to-the-general-pediatric-population-2596-5054?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC123"> Increased Prevalence of Subclinical Hypothyroidism and Thyroid Autoimmunity in Depressed Adolescents: Results From a Clinical Cross-Sectional Study in Comparison to the General Pediatric Population</a></li> </ul>]]></content:encoded>
			<enclosure length="14793646" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC123.mp3?dest-id=744856" />
			<itunes:duration>10:15</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[From the various references cited in this episode, the metamessage is clear: Thyroid hormone belongs in the treatment toolkit of psychiatric specialists, and monitoring of TSH is our responsibility.  Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Principles for Managing Alcohol Use Disorder</title>
			<itunes:title>Principles for Managing Alcohol Use Disorder</itunes:title>
			<pubDate>Sat, 13 Nov 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[4b2c807a-22fe-4323-b7f7-4d81953ded60]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/principles-for-managing-alcohol-use-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the 3 approaches in the treatment of substance use disorders: Medications for alcohol use disorder, counseling, and 12-Step facilitation.</p> <p>Faculty: Joji Suzuki, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> <strong>Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clinical-principles-on-managing-alcohol-use-disorder-2494-5059?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> <strong>Clinical Principles on Managing Alcohol Use Disorder</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the 3 approaches in the treatment of substance use disorders: Medications for alcohol use disorder, counseling, and 12-Step facilitation.</p> <p>Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/clinical-principles-on-managing-alcohol-use-disorder-2494-5059?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC122"> Clinical Principles on Managing Alcohol Use Disorder</a></li> </ul>]]></content:encoded>
			<enclosure length="10899959" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC122.mp3?dest-id=744856" />
			<itunes:duration>07:33</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the 3 approaches in the treatment of substance use disorders: Medications for alcohol use disorder, counseling, and 12-Step facilitation. Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>ECT for Depressed Patients With Borderline Personality Disorder</title>
			<itunes:title>ECT for Depressed Patients With Borderline Personality Disorder</itunes:title>
			<pubDate>Mon, 08 Nov 2021 17:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ea8b7975-b9e6-4aa8-85e7-379ca3405bd4]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/ect-for-depressed-patients-with-borderline-personality-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Previous recommendations and even APA guidelines have suggested that electroconvulsive therapy for depression is not as effective for patients with borderline personality disorder as it is for those without. This retrospective analysis of data from McLean Hospital suggests this assumption is not correct.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-28-2596?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> <strong>Earn 0.5 CMEs: Quick Take Vol. 28</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/treatment-outcomes-of-electroconvulsive-therapy-for-depressed-patients-with-and-without-borderline-personality-disorder-a-retrospective-cohort-study-2596-5050?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> <strong>Treatment Outcomes of Electroconvulsive Therapy for Depressed Patients With and Without Borderline Personality Disorder: A Retrospective Cohort Study</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Previous recommendations and even APA guidelines have suggested that electroconvulsive therapy for depression is not as effective for patients with borderline personality disorder as it is for those without. This retrospective analysis of data from McLean Hospital suggests this assumption is not correct.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-28-2596?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> Earn 0.5 CMEs: Quick Take Vol. 28</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/treatment-outcomes-of-electroconvulsive-therapy-for-depressed-patients-with-and-without-borderline-personality-disorder-a-retrospective-cohort-study-2596-5050?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC121"> Treatment Outcomes of Electroconvulsive Therapy for Depressed Patients With and Without Borderline Personality Disorder: A Retrospective Cohort Study</a></li> </ul>]]></content:encoded>
			<enclosure length="12411905" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC121.mp3?dest-id=744856" />
			<itunes:duration>08:36</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Previous recommendations and even APA guidelines have suggested that electroconvulsive therapy for depression is not as effective for patients with borderline personality disorder as it is for those without. This retrospective analysis of data from...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Assessing and Treating Alcohol Withdrawal</title>
			<itunes:title>Assessing and Treating Alcohol Withdrawal</itunes:title>
			<pubDate>Wed, 03 Nov 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[0915e916-1ef5-4892-a4ac-c8476a2a9c83]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/nlgdjaxo8kjk]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses alcohol withdrawal symptoms and consequences, including delirium tremens, management of alcohol withdrawal, and when to use symptom-triggered therapy or fixed-dose regimens. </p> <p>Faculty: Joji Suzuki, M.D.<br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> <strong>Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/consequences-of-alcohol-use-disorder-withdrawal-2494-5057?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> <strong>Consequences of Alcohol Use Disorder: Withdrawal</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses alcohol withdrawal symptoms and consequences, including delirium tremens, management of alcohol withdrawal, and when to use symptom-triggered therapy or fixed-dose regimens. </p> <p>Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/what-clinicians-need-to-know-about-alcohol-use-disorder-2494?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> Earn 1 CME: What Clinicians Need to Know About Alcohol Use Disorder</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/consequences-of-alcohol-use-disorder-withdrawal-2494-5057?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC120"> Consequences of Alcohol Use Disorder: Withdrawal</a></li> </ul>]]></content:encoded>
			<enclosure length="12942525" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC120.mp3?dest-id=744856" />
			<itunes:duration>08:58</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses alcohol withdrawal symptoms and consequences, including delirium tremens, management of alcohol withdrawal, and when to use symptom-triggered therapy or fixed-dose regimens.  Faculty: Joji Suzuki, M.D. Hosts: Jessica Diaz,...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Lab Tests in Psychopharmacology</title>
			<itunes:title>Lab Tests in Psychopharmacology</itunes:title>
			<pubDate>Fri, 29 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[3f49ea8e-55cb-41bf-81aa-b3457e648a3b]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/lab-tests-in-psychopharmacology]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Laboratory testing is essential in the practice of psychopharmacology. For example, which parameters should be monitored in patients taking carbamazepine, TCAs, atypical antipsychotics, or esketamine?</p> <p>Guest: Sandra Jacobson, M.D.;<br /> Interviewer: Mohan Gautam., D.O.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC119"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/laboratory-testing-in-the-practice-of-psychopharmacology-interview-2560?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC119"> <strong>Earn 0.5 CMEs: Laboratory Testing in the Practice of Psychopharmacology - Interview with Sandra A. Jacobson, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Laboratory testing is essential in the practice of psychopharmacology. For example, which parameters should be monitored in patients taking carbamazepine, TCAs, atypical antipsychotics, or esketamine?</p> <p>Guest: Sandra Jacobson, M.D.; Interviewer: Mohan Gautam., D.O. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC119"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/laboratory-testing-in-the-practice-of-psychopharmacology-interview-2560?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC119"> Earn 0.5 CMEs: Laboratory Testing in the Practice of Psychopharmacology - Interview with Sandra A. Jacobson, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="26912599" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC119.mp3?dest-id=744856" />
			<itunes:duration>18:42</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Laboratory testing is essential in the practice of psychopharmacology. For example, which parameters should be monitored in patients taking carbamazepine, TCAs, atypical antipsychotics, or esketamine? Guest: Sandra Jacobson, M.D.; Interviewer: Mohan...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Technology-Facilitated Adherence Enhancement and Family Involvement</title>
			<itunes:title>Technology-Facilitated Adherence Enhancement and Family Involvement</itunes:title>
			<pubDate>Sun, 24 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[33f4a884-b031-4e5a-98bf-4d8afe86955a]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/technology-facilitated-adherence-enhancement-and-family-involvement]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses technology-facilitated adherence enhancement, including text messaging, a wireless system to track adherence, and the evidence of technology-facilitated adherence for patients with bipolar disorder. It also addresses an ecological momentary intervention and the involvement of family in treatment adherence.</p> <p>Faculty: Martha Sajatovic, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> <strong>Earn 1 CME: Psychotropic Drug Adherence</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/technology-facilitated-adherence-enhancement-and-family-involvement-2606-5041?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> <strong>Technology-Facilitated Adherence Enhancement and Family Involvement</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses technology-facilitated adherence enhancement, including text messaging, a wireless system to track adherence, and the evidence of technology-facilitated adherence for patients with bipolar disorder. It also addresses an ecological momentary intervention and the involvement of family in treatment adherence.</p> <p>Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> Earn 1 CME: Psychotropic Drug Adherence</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/technology-facilitated-adherence-enhancement-and-family-involvement-2606-5041?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC118"> Technology-Facilitated Adherence Enhancement and Family Involvement</a></li> </ul>]]></content:encoded>
			<enclosure length="13212506" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC118.mp3?dest-id=744856" />
			<itunes:duration>09:09</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses technology-facilitated adherence enhancement, including text messaging, a wireless system to track adherence, and the evidence of technology-facilitated adherence for patients with bipolar disorder. It also addresses an...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Drug-Induced Hyperthermic Syndromes in Psychiatry</title>
			<itunes:title>Drug-Induced Hyperthermic Syndromes in Psychiatry</itunes:title>
			<pubDate>Tue, 19 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[df2921d7-362f-498e-b16f-8fc70f4e83cc]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/drug-induced-hyperthermic-syndromes-in-psychiatry]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>When a patient presents with markedly elevated temperature and altered mental status, is it neuroleptic malignant syndrome or serotonin syndrome? If you do not have a medication list, some clinical signs may help.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> <strong>Earn 0.5 CMEs: Quick Take Vol. 27</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/drug-induced-hyperthermic-syndromes-in-psychiatry-2591-5045?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> <strong>Drug-Induced Hyperthermic Syndromes in Psychiatry</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>When a patient presents with markedly elevated temperature and altered mental status, is it neuroleptic malignant syndrome or serotonin syndrome? If you do not have a medication list, some clinical signs may help.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> Earn 0.5 CMEs: Quick Take Vol. 27</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/drug-induced-hyperthermic-syndromes-in-psychiatry-2591-5045?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC117"> Drug-Induced Hyperthermic Syndromes in Psychiatry</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="14136217" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC117.mp3?dest-id=744856" />
			<itunes:duration>09:48</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[When a patient presents with markedly elevated temperature and altered mental status, is it neuroleptic malignant syndrome or serotonin syndrome? If you do not have a medication list, some clinical signs may help. Faculty: Jim Phelps, M.D. Hosts:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>How to Improve Adherence: Targeting Reasons for Nonadherence</title>
			<itunes:title>How to Improve Adherence: Targeting Reasons for Nonadherence</itunes:title>
			<pubDate>Thu, 14 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b214a7b9-11f1-4eb2-b5d5-e58a61a6ef0d]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/how-to-improve-adherence-targeting-reasons-for-nonadherence]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses how to improve psychotropic drug adherence by targeting the reasons for nonadherence. It also discusses a 3-tiered approach to enhancing adherence, a patient questionnaire to evaluate the reasons for not taking medications, the top reasons for poor antipsychotic adherence, and the positive aspects of taking medications. Finally, it explains other approaches to improve adherence, such as simplifying the dosing regimen.</p> <p>Faculty: Martha Sajatovic, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> Earn 1 CME: Psychotropic Drug Adherence</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/improving-psychotropic-drug-adherence-targeting-reasons-for-nonadherence-and-the-3-tiered-approach-to-enhancing-adherence-2606-5040?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> Improving Psychotropic Drug Adherence: Targeting Reasons for Nonadherence and the 3-Tiered Approach to Enhancing Adherence</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses how to improve psychotropic drug adherence by targeting the reasons for nonadherence. It also discusses a 3-tiered approach to enhancing adherence, a patient questionnaire to evaluate the reasons for not taking medications, the top reasons for poor antipsychotic adherence, and the positive aspects of taking medications. Finally, it explains other approaches to improve adherence, such as simplifying the dosing regimen.</p> <p>Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> Earn 1 CME: Psychotropic Drug Adherence</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/improving-psychotropic-drug-adherence-targeting-reasons-for-nonadherence-and-the-3-tiered-approach-to-enhancing-adherence-2606-5040?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC116"> Improving Psychotropic Drug Adherence: Targeting Reasons for Nonadherence and the 3-Tiered Approach to Enhancing Adherence</a></li> </ul>]]></content:encoded>
			<enclosure length="12356108" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC116.mp3?dest-id=744856" />
			<itunes:duration>08:34</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses how to improve psychotropic drug adherence by targeting the reasons for nonadherence. It also discusses a 3-tiered approach to enhancing adherence, a patient questionnaire to evaluate the reasons for not taking medications, the...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Esketamine: Postmarketing Safety Concerns</title>
			<itunes:title>Esketamine: Postmarketing Safety Concerns</itunes:title>
			<pubDate>Sat, 09 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[1b2ce3a8-591d-4b2e-be85-148581746102]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/esketamine-postmarketing-safety-concerns]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Earn 0.5 CMEs: Quick Take Vol. 27</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-5046?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> Earn 0.5 CMEs: Quick Take Vol. 27</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-5046?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="13968197" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC115.mp3?dest-id=744856" />
			<itunes:duration>09:41</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.       ]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Nonadherence: Adverse Drug Reactions and Measuring Perceived Side Effects With FIBSER</title>
			<itunes:title>Nonadherence: Adverse Drug Reactions and Measuring Perceived Side Effects With FIBSER</itunes:title>
			<pubDate>Mon, 04 Oct 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[55c03b20-66b3-45bf-a128-ce5fac69a6c8]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/nonadherence-adverse-drug-reactions-and-measuring-perceived-side-effects-with-fibser]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses an algorithm for assessing adherence; the reasons for suboptimal adherence, including adverse drug reactions; measuring perceived side effects with the FIBSER scale; and how to help individuals communicate with providers about side effects.</p> <p>Faculty: Martha Sajatovic, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> Earn 1 CME: Psychotropic Drug Adherence</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/nonadherence-adverse-drug-reactions-measuring-perceived-side-effects-with-fibser-and-communication-about-side-effects-2606-5039?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> <strong>Nonadherence: Adverse Drug Reactions, Measuring Perceived Side Effects With FIBSER, and Communication About Side Effects</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses an algorithm for assessing adherence; the reasons for suboptimal adherence, including adverse drug reactions; measuring perceived side effects with the FIBSER scale; and how to help individuals communicate with providers about side effects.</p> <p>Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> Earn 1 CME: Psychotropic Drug Adherence</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/nonadherence-adverse-drug-reactions-measuring-perceived-side-effects-with-fibser-and-communication-about-side-effects-2606-5039?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC114"> Nonadherence: Adverse Drug Reactions, Measuring Perceived Side Effects With FIBSER, and Communication About Side Effects</a></li> </ul>]]></content:encoded>
			<enclosure length="15076395" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC114.mp3?dest-id=744856" />
			<itunes:duration>10:27</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses an algorithm for assessing adherence; the reasons for suboptimal adherence, including adverse drug reactions; measuring perceived side effects with the FIBSER scale; and how to help individuals communicate with providers about...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Neurocovid: Pharmacologic Recommendations for Delirium Associated With COVID-19</title>
			<itunes:title>Neurocovid: Pharmacologic Recommendations for Delirium Associated With COVID-19</itunes:title>
			<pubDate>Wed, 29 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[fe4e674f-1f00-4ad8-be2e-2398b9182bfe]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/neurocovid-pharmacologic-recommendations-for-delirium-associated-with-covid-19]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Delirium has been frequently found in patients who test positive for COVID-19. It has additional features that we do not typically see in ordinary delirium. The critical question is: How do you manage these patients?</p> <p>Guest: Scott Beach, M.D.<br /> Interviewer: Wegdan Rashad, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC113"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/neurocovid-pharmacological-recommendations-for-delirium-associated-with-covid-19-interview-2598?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC113"> <strong>Earn 0.5 CMEs: Neurocovid: Pharmacological recommendations for delirium associated with COVID-19 - Interview with Scott R. Beach, M.D.</strong></a></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>Delirium has been frequently found in patients who test positive for COVID-19. It has additional features that we do not typically see in ordinary delirium. The critical question is: How do you manage these patients?</p> <p>Guest: Scott Beach, M.D. Interviewer: Wegdan Rashad, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC113"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/neurocovid-pharmacological-recommendations-for-delirium-associated-with-covid-19-interview-2598?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC113"> Earn 0.5 CMEs: Neurocovid: Pharmacological recommendations for delirium associated with COVID-19 - Interview with Scott R. Beach, M.D.</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="24433456" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC113.mp3?dest-id=744856" />
			<itunes:duration>16:57</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Delirium has been frequently found in patients who test positive for COVID-19. It has additional features that we do not typically see in ordinary delirium. The critical question is: How do you manage these patients? Guest: Scott Beach, M.D....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>How to Assess Psychotropic Drug Adherence</title>
			<itunes:title>How to Assess Psychotropic Drug Adherence</itunes:title>
			<pubDate>Fri, 24 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[0d8a6cf7-6be2-4978-978b-7d240c238286]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/how-to-assess-psychotropic-drug-adherence]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the assessment of adherence: Self-report, electronic medication monitoring systems, rating scales, medication possession ratio, questions for assessing medication adherence, and the recommended frequency of adherence monitoring. </p> <p>Faculty: Martha Sajatovic, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> Earn 1 CME: Psychotropic Drug Adherence</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/assessing-adherence-self-report-rating-scales-medication-refills-automated-pill-taking-frequency-monitoring-medication-routines-and-duration-of-assessments-2606-5038?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> Assessing Adherence: Self-Report, Rating Scales, Medication Refills, Automated Pill-Taking Frequency Monitoring, Medication Routines, and Duration of Assessments</a></strong></li> </ul> <p> </p>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the assessment of adherence: Self-report, electronic medication monitoring systems, rating scales, medication possession ratio, questions for assessing medication adherence, and the recommended frequency of adherence monitoring. </p> <p>Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/psychotropic-drug-adherence-2606?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> Earn 1 CME: Psychotropic Drug Adherence</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/assessing-adherence-self-report-rating-scales-medication-refills-automated-pill-taking-frequency-monitoring-medication-routines-and-duration-of-assessments-2606-5038?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC112"> Assessing Adherence: Self-Report, Rating Scales, Medication Refills, Automated Pill-Taking Frequency Monitoring, Medication Routines, and Duration of Assessments</a></li> </ul> <p> </p>]]></content:encoded>
			<enclosure length="18016738" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC112.mp3?dest-id=744856" />
			<itunes:duration>12:30</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the assessment of adherence: Self-report, electronic medication monitoring systems, rating scales, medication possession ratio, questions for assessing medication adherence, and the recommended frequency of adherence...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD)</title>
			<itunes:title>Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD)</itunes:title>
			<pubDate>Sun, 19 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ec577e6e-8382-47b5-bfd9-496b18a25090]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/citalopram-for-acute-and-preventive-efficacy-in-bipolar-depression-cape-bd]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>A new randomized trial suggests that the efficacy of antidepressants for the treatment of bipolar depression is no greater than placebo. This tips the meta-analytic balance scale, which already pointed in this direction.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-26-2580?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> Earn 0.5 CMEs: Quick Take Vol. 26</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/citalopram-for-acute-and-preventive-efficacy-in-bipolar-depression-cape-bd-a-randomized-double-blind-placebo-controlled-trial-2580-5033?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> <strong>Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>A new randomized trial suggests that the efficacy of antidepressants for the treatment of bipolar depression is no greater than placebo. This tips the meta-analytic balance scale, which already pointed in this direction.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-26-2580?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> Earn 0.5 CMEs: Quick Take Vol. 26</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/citalopram-for-acute-and-preventive-efficacy-in-bipolar-depression-cape-bd-a-randomized-double-blind-placebo-controlled-trial-2580-5033?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC111"> Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial</a></li> </ul>]]></content:encoded>
			<enclosure length="14194292" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC111.mp3?dest-id=744856" />
			<itunes:duration>09:50</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[A new randomized trial suggests that the efficacy of antidepressants for the treatment of bipolar depression is no greater than placebo. This tips the meta-analytic balance scale, which already pointed in this direction. Faculty: Jim Phelps, M.D....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Delirium, Catatonia, and COVID-19</title>
			<itunes:title>Delirium, Catatonia, and COVID-19</itunes:title>
			<pubDate>Tue, 14 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[e888a0af-9280-43b6-99a3-b0b4079997ed]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/delirium-catatonia-and-covid-19]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This podcast offers a discussion on catatonia and delirium as well as treatments for their co-occurrence. Treatments discussed include benzodiazepines, amantadine, and memantine. We also address the management of COVID-19 delirium with antipsychotics.</p> <p>Faculty: Scott Beach, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> Earn 1 CME: Management of Delirium</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/special-considerations-in-delirium-catatonia-and-covid-19-2593-5027?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> <strong>Special Considerations in Delirium: Catatonia and COVID-19</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This podcast offers a discussion on catatonia and delirium as well as treatments for their co-occurrence. Treatments discussed include benzodiazepines, amantadine, and memantine. We also address the management of COVID-19 delirium with antipsychotics.</p> <p>Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> Earn 1 CME: Management of Delirium</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/special-considerations-in-delirium-catatonia-and-covid-19-2593-5027?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC110"> Special Considerations in Delirium: Catatonia and COVID-19</a></li> </ul>]]></content:encoded>
			<enclosure length="11912465" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC110.mp3?dest-id=744856" />
			<itunes:duration>08:15</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This podcast offers a discussion on catatonia and delirium as well as treatments for their co-occurrence. Treatments discussed include benzodiazepines, amantadine, and memantine. We also address the management of COVID-19 delirium with antipsychotics....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder</title>
			<itunes:title>Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder</itunes:title>
			<pubDate>Thu, 09 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[9779f3e7-d597-4d9c-9cf2-784c365e2080]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/effects-of-psilocybin-assisted-therapy-on-major-depressive-disorder]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Is psilocybin a potential treatment for major depression? There's certainly been a lot of press coverage, but to date, the reports are largely open trials in a variety of conditions, including OCD, substance use, PTSD, and patients with cancer and psychological distress. Against that backdrop, a randomized trial of psilocybin for major depression is an exciting new step.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-26-2580?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> Earn 0.5 CMEs: Quick Take Vol. 26</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/effects-of-psilocybin-assisted-therapy-on-major-depressive-disorder-a-randomized-clinical-trial-2580-5031?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Is psilocybin a potential treatment for major depression? There's certainly been a lot of press coverage, but to date, the reports are largely open trials in a variety of conditions, including OCD, substance use, PTSD, and patients with cancer and psychological distress. Against that backdrop, a randomized trial of psilocybin for major depression is an exciting new step.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-26-2580?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> Earn 0.5 CMEs: Quick Take Vol. 26</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/effects-of-psilocybin-assisted-therapy-on-major-depressive-disorder-a-randomized-clinical-trial-2580-5031?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC109"> Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial</a></li> </ul>]]></content:encoded>
			<enclosure length="11778697" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC109.mp3?dest-id=744856" />
			<itunes:duration>08:10</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Is psilocybin a potential treatment for major depression? There's certainly been a lot of press coverage, but to date, the reports are largely open trials in a variety of conditions, including OCD, substance use, PTSD, and patients with cancer and...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Dopamine and Depression: Clinical Considerations</title>
			<itunes:title>Dopamine and Depression: Clinical Considerations</itunes:title>
			<pubDate>Sat, 04 Sep 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c4ca89fe-69b2-4ab7-902c-04b2287a6235]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/dopamine-and-depression-clinical-considerations]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease.</p> <p>Guest: Ken Gillman, M.D.;<br /> Interviewer: Wegdan Rashad, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/dopamine-and-depression-clinical-considerations-interview-2599?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> <strong>Earn 0.5 CMEs: Dopamine and Depression: Clinical Considerations - Interview with Ken Gillman, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease.</p> <p>Guest: Ken Gillman, M.D.; Interviewer: Wegdan Rashad, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/dopamine-and-depression-clinical-considerations-interview-2599?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC108"> Earn 0.5 CMEs: Dopamine and Depression: Clinical Considerations - Interview with Ken Gillman, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="21379867" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC108.mp3?dest-id=744856" />
			<itunes:duration>14:50</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease....]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium</title>
			<itunes:title>Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium</itunes:title>
			<pubDate>Mon, 30 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[518847a2-6a41-4f54-b31a-15f03d68bcbe]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/haloperidol-chlorpromazine-and-atypical-antipsychotics-for-managing-delirium]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This podcast offers a discussion on the use of antipsychotics for managing delirium. Topics covered include: Choosing an antipsychotic, the advantages of IV haloperidol, different dosing strategies, and concerns regarding QT prolongation. We also examine chlorpromazine, olanzapine, quetiapine, and aripiprazole for managing delirium.</p> <p>Faculty: Scott Beach, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> Earn 1 CME: Management of Delirium</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/haloperidol-chlorpromazine-and-atypical-antipsychotics-for-managing-delirium-2593-5024?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> <strong>Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This podcast offers a discussion on the use of antipsychotics for managing delirium. Topics covered include: Choosing an antipsychotic, the advantages of IV haloperidol, different dosing strategies, and concerns regarding QT prolongation. We also examine chlorpromazine, olanzapine, quetiapine, and aripiprazole for managing delirium.</p> <p>Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> Earn 1 CME: Management of Delirium</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/haloperidol-chlorpromazine-and-atypical-antipsychotics-for-managing-delirium-2593-5024?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC107"> Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium</a></li> </ul>]]></content:encoded>
			<enclosure length="27776921" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC107.mp3?dest-id=744856" />
			<itunes:duration>19:16</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This podcast offers a discussion on the use of antipsychotics for managing delirium. Topics covered include: Choosing an antipsychotic, the advantages of IV haloperidol, different dosing strategies, and concerns regarding QT prolongation. We also...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>New Somatic Treatments for Child and Adolescent Depression</title>
			<itunes:title>New Somatic Treatments for Child and Adolescent Depression</itunes:title>
			<pubDate>Wed, 25 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[33df8d2a-fd7e-429d-afef-9c1ce70e75eb]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/new-somatic-treatments-for-child-and-adolescent-depression]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram.<br /> What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS).</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> <strong>Earn 0.5 CMEs: Quick Take Vol. 25</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/new-somatic-treatments-for-child-and-adolescent-depression-part-1-2578-5017?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> <strong>New Somatic Treatments for Child and Adolescent Depression (Part 1) </strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram. What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS).</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> Earn 0.5 CMEs: Quick Take Vol. 25</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/new-somatic-treatments-for-child-and-adolescent-depression-part-1-2578-5017?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106"> New Somatic Treatments for Child and Adolescent Depression (Part 1) </a></li> </ul>]]></content:encoded>
			<enclosure length="14477439" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC106.mp3?dest-id=744856" />
			<itunes:duration>10:02</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram. What works besides routine first-line approaches? This episode discusses options to consider:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Management of Delirium: Nonpharmacologic Strategies</title>
			<itunes:title>Management of Delirium: Nonpharmacologic Strategies</itunes:title>
			<pubDate>Fri, 20 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[ac2c45eb-7006-4b41-91c5-d597e3ad6689]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/management-of-delirium-nonpharmacologic-strategies]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses nonpharmacologic management strategies for delirium, such as the ones included in the ABCDE bundle.</p> <p>Faculty: Scott Beach, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> Earn 1 CME: Management of Delirium</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/section/management-of-delirium-nonpharmacologic-strategies-2593-5023?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> <strong>Management of Delirium: Nonpharmacologic Strategies</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses nonpharmacologic management strategies for delirium, such as the ones included in the ABCDE bundle.</p> <p>Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> Earn 1 CME: Management of Delirium</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/management-of-delirium-nonpharmacologic-strategies-2593-5023?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC105"> Management of Delirium: Nonpharmacologic Strategies</a></li> </ul>]]></content:encoded>
			<enclosure length="7140207" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC105.mp3?dest-id=744856" />
			<itunes:duration>04:56</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses nonpharmacologic management strategies for delirium, such as the ones included in the ABCDE bundle. Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Emerging Complementary and Integrative Therapies for Geriatric Mental Health</title>
			<itunes:title>Emerging Complementary and Integrative Therapies for Geriatric Mental Health</itunes:title>
			<pubDate>Sun, 15 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[f3364571-a9ef-4676-ab8c-368ff4237216]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/emerging-complementary-and-integrative-therapies-for-geriatric-mental-health]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Are there any alternative medicine treatments that might be useful for your geriatric patients? We examine the evidence base for diet, herbal and nutritional supplements, and mind–body therapies for the prevention of dementia and the treatment of depression.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> <strong>Earn 0.5 CMEs: Quick Take Vol. 25</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/emerging-complementary-and-integrative-therapies-for-geriatric-mental-health-2578-5016?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> <strong>Emerging Complementary and Integrative Therapies for Geriatric Mental Health</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Are there any alternative medicine treatments that might be useful for your geriatric patients? We examine the evidence base for diet, herbal and nutritional supplements, and mind–body therapies for the prevention of dementia and the treatment of depression.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> Earn 0.5 CMEs: Quick Take Vol. 25</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/emerging-complementary-and-integrative-therapies-for-geriatric-mental-health-2578-5016?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC104"> Emerging Complementary and Integrative Therapies for Geriatric Mental Health</a></li> </ul>]]></content:encoded>
			<enclosure length="13428173" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC104.mp3?dest-id=744856" />
			<itunes:duration>09:18</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Are there any alternative medicine treatments that might be useful for your geriatric patients? We examine the evidence base for diet, herbal and nutritional supplements, and mind–body therapies for the prevention of dementia and the treatment of...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Delirium: Assessment, Consequences, and Sequelae</title>
			<itunes:title>Delirium: Assessment, Consequences, and Sequelae</itunes:title>
			<pubDate>Tue, 10 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[eccabff4-9ead-4489-8e11-7f76997a33ce]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/delirium-assessment-consequences-and-sequelae]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the assessment of delirium. This includes: EEG and neurological exam, cognitive dysfunctions present in delirium, recommended testing, differential diagnoses, and the consequences of delirium.</p> <p>Faculty: Scott Beach, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> Earn 1 CME: Management of Delirium</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/delirium-assessment-consequences-and-sequelae-2593-5020?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> Delirium: Assessment, Consequences and Sequelae</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the assessment of delirium. This includes: EEG and neurological exam, cognitive dysfunctions present in delirium, recommended testing, differential diagnoses, and the consequences of delirium.</p> <p>Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/management-of-delirium-2593?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> Earn 1 CME: Management of Delirium</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/delirium-assessment-consequences-and-sequelae-2593-5020?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC103"> Delirium: Assessment, Consequences and Sequelae</a></li> </ul>]]></content:encoded>
			<enclosure length="14915502" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC103.mp3?dest-id=744856" />
			<itunes:duration>10:20</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the assessment of delirium. This includes: EEG and neurological exam, cognitive dysfunctions present in delirium, recommended testing, differential diagnoses, and the consequences of delirium. Faculty: Scott Beach, M.D. Hosts:...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>In Search of a Dose-Response Relationship in SSRIs</title>
			<itunes:title>In Search of a Dose-Response Relationship in SSRIs</itunes:title>
			<pubDate>Thu, 05 Aug 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b894f551-c006-460d-b1d2-ecdc88995dc5]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/in-search-of-a-dose-response-relationship-in-ssris]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>A meta-analysis of antidepressant doses and responses finds no evidence of improved outcomes with higher doses, just more side effects. However, this conclusion is based on fixed-dose comparison studies, which do not mirror the way we practice. Here we'll compare the lack of evidence for a dose-response relationship to your clinical practice.</p> <p>Faculty:  Jim Phelps<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-24-2573?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> <strong>Earn 0.5 CMEs: Quick Take Vol. 24</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/in-search-of-a-dose-response-relationship-in-ssrisa-systematic-review-meta-analysis-and-network-meta-analysis-2573-4992?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> <strong>In Search of a Dose-Response Relationship in SSRIs—A Systematic Review, Meta-Analysis, and Network Meta-Analysis</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>A meta-analysis of antidepressant doses and responses finds no evidence of improved outcomes with higher doses, just more side effects. However, this conclusion is based on fixed-dose comparison studies, which do not mirror the way we practice. Here we'll compare the lack of evidence for a dose-response relationship to your clinical practice.</p> <p>Faculty:  Jim Phelps Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-24-2573?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> Earn 0.5 CMEs: Quick Take Vol. 24</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/in-search-of-a-dose-response-relationship-in-ssrisa-systematic-review-meta-analysis-and-network-meta-analysis-2573-4992?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC102"> In Search of a Dose-Response Relationship in SSRIs—A Systematic Review, Meta-Analysis, and Network Meta-Analysis</a></li> </ul>]]></content:encoded>
			<enclosure length="12063724" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC102.mp3?dest-id=744856" />
			<itunes:duration>08:22</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[A meta-analysis of antidepressant doses and responses finds no evidence of improved outcomes with higher doses, just more side effects. However, this conclusion is based on fixed-dose comparison studies, which do not mirror the way we practice. Here...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Valproate/Divalproex: Metabolism, Kinetics, and Warnings</title>
			<itunes:title>Valproate/Divalproex: Metabolism, Kinetics, and Warnings</itunes:title>
			<pubDate>Sat, 31 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[c2e061ec-3c1e-48bf-8313-498d78fc4f96]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/valproatedivalproex-metabolism-kinetics-and-warnings]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses valproate kinetics and sublinear kinetics, valproic acid levels, its absolute contraindications, and what to consider when using the package insert.</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> <strong>Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/valproatedivalproex-metabolism-kinetics-and-warnings-2582-5010?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> <strong>Valproate/Divalproex: Metabolism, Kinetics, and Warnings</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses valproate kinetics and sublinear kinetics, valproic acid levels, its absolute contraindications, and what to consider when using the package insert.</p> <p>Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/valproatedivalproex-metabolism-kinetics-and-warnings-2582-5010?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC101"> Valproate/Divalproex: Metabolism, Kinetics, and Warnings</a></li> </ul>]]></content:encoded>
			<enclosure length="11792720" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC101.mp3?dest-id=744856" />
			<itunes:duration>08:10</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses valproate kinetics and sublinear kinetics, valproic acid levels, its absolute contraindications, and what to consider when using the package insert. Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Managing Drug-Induced Movement Disorders</title>
			<itunes:title>Managing Drug-Induced Movement Disorders</itunes:title>
			<pubDate>Mon, 26 Jul 2021 13:29:35 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[87effa5b-dba1-46be-89ba-4d44f0d0e41f]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/managing-drug-induced-movement-disorders]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>A practical discussion on akathisia, extrapyramidal symptoms (EPS), tardive syndromes, and acute dystonia.</p> <p>Guest: Gregory Pontone, M.D. <br /> Interviewer: Mohan Gautam, D.O.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC100"> Learn more about our memberships here</a></strong></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/drug-induced-movement-disorders-the-clinical-essentials-interview-2522?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC100"> <strong>Earn 0.5 CMEs: Drug-Induced Movement Disorders: The Clinical Essentials - Interview with Gregory Pontone, M.D.</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>A practical discussion on akathisia, extrapyramidal symptoms (EPS), tardive syndromes, and acute dystonia.</p> <p>Guest: Gregory Pontone, M.D.  Interviewer: Mohan Gautam, D.O. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC100"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/drug-induced-movement-disorders-the-clinical-essentials-interview-2522?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC100"> Earn 0.5 CMEs: Drug-Induced Movement Disorders: The Clinical Essentials - Interview with Gregory Pontone, M.D.</a></li> </ul>]]></content:encoded>
			<enclosure length="21055113" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC100.mp3?dest-id=744856" />
			<itunes:duration>14:36</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[A practical discussion on akathisia, extrapyramidal symptoms (EPS), tardive syndromes, and acute dystonia. Guest: Gregory Pontone, M.D.  Interviewer: Mohan Gautam, D.O. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Drug Metabolism: The Importance of Child-Pugh Classification for Staging Hepatic Impairment</title>
			<itunes:title>Drug Metabolism: The Importance of Child-Pugh Classification for Staging Hepatic Impairment</itunes:title>
			<pubDate>Wed, 21 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[d23c5c6f-b128-4da6-9d6c-d13a819a6697]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/drug-metabolism-the-importance-of-child-pugh-classification-for-staging-hepatic-impairment]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the Child-Pugh scale to assess hepatic impairment. It also covers the FDA's position on the inclusion of drug metabolism data for various Child-Pugh stages and cirrhosis.</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> <strong>Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-importance-of-child-pugh-classification-for-staging-hepatic-impairment-2582-5009?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> <strong>The Importance of Child-Pugh Classification for Staging Hepatic Impairment</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the Child-Pugh scale to assess hepatic impairment. It also covers the FDA's position on the inclusion of drug metabolism data for various Child-Pugh stages and cirrhosis.</p> <p>Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-importance-of-child-pugh-classification-for-staging-hepatic-impairment-2582-5009?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC099"> The Importance of Child-Pugh Classification for Staging Hepatic Impairment</a></li> </ul>]]></content:encoded>
			<enclosure length="10281797" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC099.mp3?dest-id=744856" />
			<itunes:duration>07:07</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the Child-Pugh scale to assess hepatic impairment. It also covers the FDA's position on the inclusion of drug metabolism data for various Child-Pugh stages and cirrhosis. Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.;...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Impact of Smoking Behavior on Clozapine Blood Levels</title>
			<itunes:title>Impact of Smoking Behavior on Clozapine Blood Levels</itunes:title>
			<pubDate>Fri, 16 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[9be224ff-9ccd-4fb2-b303-7c942033eef8]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/impact-of-smoking-behavior-on-clozapine-blood-levels]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>Clozapine blood levels can be influenced by many factors. These include dose, gender, age, body weight, caffeine, medications, and of course, smoking.<br /> How much is the reduction in clozapine levels actually due to cigarette smoking?</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-24-2573?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> Earn 0.5 CMEs: Quick Take Vol. 24</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/impact-of-smoking-behavior-on-clozapine-blood-levelsa-systematic-review-and-meta-analysis-2573-4989?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> Impact of Smoking Behavior on Clozapine Blood Levels—A Systematic Review and Meta-Analysis</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>Clozapine blood levels can be influenced by many factors. These include dose, gender, age, body weight, caffeine, medications, and of course, smoking. How much is the reduction in clozapine levels actually due to cigarette smoking?</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-24-2573?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> Earn 0.5 CMEs: Quick Take Vol. 24</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/impact-of-smoking-behavior-on-clozapine-blood-levelsa-systematic-review-and-meta-analysis-2573-4989?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC098"> Impact of Smoking Behavior on Clozapine Blood Levels—A Systematic Review and Meta-Analysis</a></li> </ul>]]></content:encoded>
			<enclosure length="11523533" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC098.mp3?dest-id=744856" />
			<itunes:duration>07:59</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[Clozapine blood levels can be influenced by many factors. These include dose, gender, age, body weight, caffeine, medications, and of course, smoking. How much is the reduction in clozapine levels actually due to cigarette smoking? Faculty: Jim...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>The Child-Pugh Scale in Psychiatry</title>
			<itunes:title>The Child-Pugh Scale in Psychiatry</itunes:title>
			<pubDate>Sun, 11 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[adb0b7b5-4910-43cc-8092-5f91394d8136]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/the-child-pugh-scale-in-psychiatry]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This episode discusses the Child-Pugh Rating Scale and how to interpret it, two clinical cases, and the use of paliperidone and lurasidone in patients with hepatic impairment (Child-Pugh C).</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> <strong>Learn more about our memberships here</strong></a></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/rating-scales-for-hepatic-dysfunction-child-pugh-2582-5008?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> Rating Scales for Hepatic Dysfunction: Child-Pugh</a></strong></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This episode discusses the Child-Pugh Rating Scale and how to interpret it, two clinical cases, and the use of paliperidone and lurasidone in patients with hepatic impairment (Child-Pugh C).</p> <p>Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/rating-scales-for-hepatic-dysfunction-child-pugh-2582-5008?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC097"> Rating Scales for Hepatic Dysfunction: Child-Pugh</a></li> </ul>]]></content:encoded>
			<enclosure length="17958662" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC097.mp3?dest-id=744856" />
			<itunes:duration>12:27</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This episode discusses the Child-Pugh Rating Scale and how to interpret it, two clinical cases, and the use of paliperidone and lurasidone in patients with hepatic impairment (Child-Pugh C). Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.;...]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Managing Neuroleptic Malignant Syndrome: An Evidence-Based Update</title>
			<itunes:title>Managing Neuroleptic Malignant Syndrome: An Evidence-Based Update</itunes:title>
			<pubDate>Tue, 06 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[20acb441-6b1f-4f11-83df-9eb68b54cbc9]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/managing-neuroleptic-malignant-syndrome-an-evidence-based-update]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How should we approach the management of neuroleptic malignant syndrome? What is the role of bromocriptine, dantrolene, and ECT?<br /> <br /> Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-23-2627?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> <strong>Earn 0.5 CMEs: Quick Take Vol. 23</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-neuroleptic-malignant-syndromea-systematic-case-series-analysis-focusing-on-therapy-regimes-and-outcome-2627-4976?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> <strong>The Neuroleptic Malignant Syndrome—A Systematic Case Series Analysis Focusing on Therapy Regimes and Outcome</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How should we approach the management of neuroleptic malignant syndrome? What is the role of bromocriptine, dantrolene, and ECT?  Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-23-2627?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> Earn 0.5 CMEs: Quick Take Vol. 23</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/the-neuroleptic-malignant-syndromea-systematic-case-series-analysis-focusing-on-therapy-regimes-and-outcome-2627-4976?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC096"> The Neuroleptic Malignant Syndrome—A Systematic Case Series Analysis Focusing on Therapy Regimes and Outcome</a></li> </ul>]]></content:encoded>
			<enclosure length="14196173" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC096.mp3?dest-id=744856" />
			<itunes:duration>09:50</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How should we approach the management of neuroleptic malignant syndrome? What is the role of bromocriptine, dantrolene, and ECT?  Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease</title>
			<itunes:title>Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease</itunes:title>
			<pubDate>Thu, 01 Jul 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[a35f3dc5-6997-49ff-a90e-23e8aec86a83]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/psychotropics-and-hepatic-issues-nonalcoholic-fatty-liver-disease]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-5007?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?</p> <p>Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-5007?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis</a></li> </ul>]]></content:encoded>
			<enclosure length="17925435" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC095.mp3?dest-id=744856" />
			<itunes:duration>12:26</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics? Faculty: Jonathan Meyer, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
		<item>
			<title>Alzheimer's Disease: Can We Lower the Risk?</title>
			<itunes:title>Alzheimer's Disease: Can We Lower the Risk?</itunes:title>
			<pubDate>Sat, 26 Jun 2021 16:00:00 +0000</pubDate>
			<guid isPermaLink="false"><![CDATA[b3b43639-065a-4ad6-98e8-570a59ccbdf5]]></guid>
			<link><![CDATA[https://psychopharmacology.libsyn.com/alzheimers-disease-can-we-lower-the-risk]]></link>
			<itunes:image href="https://ssl-static.libsyn.com/p/assets/c/e/6/c/ce6c5c791aa098b3/artwork_podcast.png" />
			<description><![CDATA[<p>This meta-analysis is a useful reminder of risk factors to look for in your patients. You can also help them understand the long-term risks of Alzheimer's disease.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-23-2627?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> <strong>Earn 0.5 CMEs: Quick Take Vol. 23</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/evidence-based-prevention-of-alzheimers-disease-systematic-review-and-meta-analysis-of-243-observational-prospective-studies-and-153-randomised-controlled-trials-2627-4972?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> <strong>Evidence-Based Prevention of Alzheimer's Disease: Systematic Review and Meta-Analysis of 243 Observational Prospective Studies and 153 Randomised Controlled Trials</strong></a></li> </ul>]]></description>
			<content:encoded><![CDATA[<p>This meta-analysis is a useful reminder of risk factors to look for in your patients. You can also help them understand the long-term risks of Alzheimer's disease.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> Learn more about our memberships here</a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-23-2627?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> Earn 0.5 CMEs: Quick Take Vol. 23</a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/evidence-based-prevention-of-alzheimers-disease-systematic-review-and-meta-analysis-of-243-observational-prospective-studies-and-153-randomised-controlled-trials-2627-4972?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC094"> Evidence-Based Prevention of Alzheimer's Disease: Systematic Review and Meta-Analysis of 243 Observational Prospective Studies and 153 Randomised Controlled Trials</a></li> </ul>]]></content:encoded>
			<enclosure length="9760811" type="audio/mpeg" url="https://traffic.libsyn.com/secure/psychopharmacology/OPC094.mp3?dest-id=744856" />
			<itunes:duration>06:46</itunes:duration>
			<itunes:explicit>false</itunes:explicit>
			<itunes:keywords />
			<itunes:subtitle><![CDATA[This meta-analysis is a useful reminder of risk factors to look for in your patients. You can also help them understand the long-term risks of Alzheimer's disease. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.]]></itunes:subtitle>
			<itunes:episodeType>full</itunes:episodeType>
		</item>
	
	</channel>
</rss>
